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ABSTRACT 
Solid tumors contain hypoxic regions due to their unchecked proliferation. This 
hypoxic microenvironment induces cancer cell metastasis and angiogenesis to promote 
tumor survival. The hypoxia-inducible factors (HIFs) are the primary regulators of the 
hypoxic response, inducing genes involved in important tumor progression pathways. 
The lysine (K)-specific demethylase KDM4B is a direct target of HIF, creating an 
intriguing link between the hypoxic tumor microenvironment and downstream gene 
expression beyond the direct actions of HIF stabilization. The findings that hypoxia-
inducible KDM4B overexpression occurs in multiple cancer types suggest a general 
KDM4B function in these cancers. However, our current knowledge on KDM4B function 
in each cancer type seems to rely on tissue-specific pathways. In a microarray analysis 
using transient knockdown of KDM4B, we identified a set of potential KDM4B targets 
with clear associations to tumor cell growth, migration, and metastasis. Microarray data 
from HCT116 colon carcinoma, SKOV3ip.1 ovarian cancer and RCC4 renal cell 
carcinoma cells identified numerous genes specifically regulated in each cell type, as 
well as 16 common targets shared by all three cell lines. Through Ingenuity Pathway 
Analysis, we found that KDM4B also regulated different pathways under different 
oxygen conditions. In general, KDM4B regulated proliferative genes in normoxia, and 
metastatic genes in hypoxia. We have also demonstrated that KDM4B regulated these 
target genes by binding and demethylating near the promoter regions of these genes. 
Our findings suggest that KDM4B regulates pathways specific to each cancer type and 
tumor microenvironment to support cancer cell survival. Hypoxia has been linked to 
poor prognosis of epithelial ovarian cancer (EOC), likely through regulating genes that 
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contribute to the widespread dissemination of peritoneal metastases observed in late-
stage diagnosis. In this study, we have shown that KDM4B is expressed in high grade 
serous adenocarcinoma and EOC cell lines, especially in hypoxia. Suppressing KDM4B 
inhibits ovarian cancer cell invasion, migration and spheroid formation in vitro. KDM4B 
is also crucial for seeding and growth of peritoneal tumors in vivo, where its expression 
corresponds to hypoxic regions. Thus, KDM4B is a potent contributor to the seeding 
and growth of peritoneal tumors, one of the predominant factors affecting prognosis of 
EOC.  
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CHAPTER 1: 
GENERAL INTRODUCTION 
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Hypoxia in Tissue 
In multicellular tissue, oxygen can only freely diffuse to cells within a distance of 
approximately 100 μm (Thomlinson and Gray 1955). Past this distance, cellular 
metabolism depletes the microenvironment of the remaining oxygen, creating a gradient 
of decreasing oxygen (hypoxia). Some organs and tissues experience hypoxic 
microenvironment due to their distance from the functional blood supply (Brigati et al. 
2010). For example, the inner part of the retina experiences a PO2 of 15-20 mm Hg (~2-
4% O2). Similarly, the kidney can sustain an oxygen level that is 7.2 mm Hg (~1% O2) 
(Birol et al. 2007; Simon and Keith 2008). This interplay between tissue vasculature and 
cellular metabolism, as illustrated in Figure 1.1, is particularly important when 
considering the role of oxygen in the tumor microenvironment. Over the past decade, 
tumors have increasingly been recognized as complex organs rather than homogenous 
tumor masses (Hanahan and Weinberg 2000). Growing evidence suggests that host 
and stromal factors in the tumor microenvironment are equally important as genetic 
events in the tumor cells. A solid tumor includes not only cancer cells but also matrix 
components, stromal cells and inflammatory cells. Moreover, due to the fast growth of 
the cancer cells, tumor vasculature usually has leaky walls. Even so, tumor 
angiogenesis is still slower than cancer cell proliferation. Therefore, solid tumors 
typically contain hypoxic regions.   
The Hypoxic Tumor Microenvironment 
Tumor hypoxia often leads to cancer malignancy and predicts a poor response to 
chemotherapy and radiation treatment (Teicher 1994; Vaupel 2004). Since these  
 3 
Figure 1.1. Schematic Diagram Showing Hypoxic and Necrotic Regions In 
Multicellular Tissues. Only cells in 100 μm distance from the blood vessel may acquire 
enough oxygen for their own growth. Beyond this distance, cells experience hypoxia. 
Further away, cells may go through necrosis.  
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regions are farther from the blood vessels, cells in this area do not obtain enough 
nutrients or oxygen. In response to this nutrient deprivation, the cells proliferate more 
slowly, decreasing efficiency of most current cancer therapies that target the actively 
proliferating cells. It is also more difficult for chemotherapeutic drugs to reach cells in 
these regions. In addition, hypoxic stress stimulates mechanisms in cells to manipulate 
their metabolism to adapt to the environment (Semenza et al. 1994), to send out signals 
for angiogenesis (Blancher et al. 2000), or to migrate to a distant location where oxygen 
is more abundant (Erler and Giaccia 2006). These cellular adaptations combined with 
the physical barriers to conventional therapies select for a more resistant tumor 
phenotype.  
The Hypoxia Inducible Factors 
In response to hypoxia, cells initiate a series of cellular responses through a 
family of transcription factors called hypoxia inducible factors (HIFs) (Semenza and 
Wang 1992; Wang and Semenza 1993a; Wang and Semenza 1993b; Semenza 1998). 
Functional HIFs are heterodimers containing an α subunit that is tightly regulated by 
oxygen concentrations and a β subunit (also called aryl hydrocarbon receptor nuclear 
translocator, ARNT) that does not respond to oxygen (Semenza et al. 1997; Majmundar 
et al. 2010). There are three identified mammalian HIF-α isoforms (HIF-1α, HIF-2α and 
HIF-3α), among which HIF-1α is the best studied (Majmundar et al. 2010). HIF-1α and 
HIF-2α share much similarity, except that HIF-1α is expressed in most tissue whereas 
HIF-2α is restricted to certain organs such as vascular endothelium and hepatocytes 
(Wiesener et al. 2003). Moreover, HIF-1α and HIF-2α share common targets but also 
regulate the expression of distinct sets of genes (Ratcliffe 2007; Loboda et al. 2010). 
 6 
HIF-3α is less related to the other two variants and not very well studied. Interestingly, 
an alternatively spliced variant of HIF-3α acts as a dominant negative regulator of HIF-
1α (Makino et al. 2001). HIF-α (HIF-1α or HIF-2α) and HIF-β together form a complex 
that binds to the hypoxia response elements (HREs) in the promoter region of target 
genes (Semenza et al. 1996; Koi and Boland 2011).  
When oxygen is sufficient, HIF-1α is constantly degraded through binding and 
ubiquitylation of the tumor suppressor protein von Hippel-Lindal (VHL), which is a part of 
the E3 ubiquitin ligase complex (Maxwell et al. 1999; Ohh et al. 2000). HIF-alpha prolyl 
hydroxylases (PHDs) regulate this binding between HIF-1α and VHL by hydroxylating 
proline residue 402 and 564 in the HIF-1α subunit (Ivan et al. 2001; Jaakkola et al. 
2001; Chan et al. 2002; Chan et al. 2005). Since proline hydroxylation requires oxygen, 
PHDs are inhibited under hypoxia, HIF-1α is then stabilized and is able to interact with 
the β-subunit (ARNT) and additional co-activators (Rohwer and Cramer 2011) (Figure 
1.2).  
Factor inhibiting HIF1 (FIH1) is another oxygen-sensitive enzyme that 
hydroxylates HIF-1α asparagine 803 (Mahon et al. 2001; Lando et al. 2002; McNeill et 
al. 2002). This hydroxylation blocks the interaction between HIF-1α and the co-
activators p300 and CREB binding protein (CBP) (Mahon et al. 2001). Hypoxia disrupts 
FIH1 enzymatic activity, enabling interaction of the HIF1/CBP/p300 complex, and 
enhancing transcription of HIF target genes (Yang et al. 2009).  
HIF is a master regulator of a number of downstream target genes involved in 
various pathways. Vascular endothelial growth factor (VEGF) is associated with poor 
prognosis in various cancer types (Blancher et al. 2000; Jones et al. 2001). Its  
 7 
Figure 1.2. Schematic Diagram Showing HIF-1α Stabilization in Hypoxia. In 
normoxia, HIF-1α is hydroxylated by PHD2 and ubiquitilated by VHL for proteasome 
degradation. In hypoxia, PHD activity is inhibited and HIF-1α is stabilized and dimerizes 
with ARNT to activated transcription of target genes.  
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expression is significantly increased under hypoxia and this pattern is regulated by HIF 
(Forsythe et al. 1996). Lysyl oxidase (LOX) is involved in tumor metastasis in response 
to hypoxia (Erler et al. 2006). Prolyl hydroxylase domain protein 2 (PHD2) exerts tumor-
suppressive activity in pancreatic cancer, osteosarcoma, melanoma, and lung cancer. 
(Metzen et al. 2005; Ameln et al. 2011; Su et al. 2011). Urokinase-type plasminogen 
activator receptor (u-PAR) is part of the plasminogen activator system (PAS), which 
contributes to the metastasis and angiogenesis of malignant tumors (Oszajca et al. 
2008; Halamkova et al. 2011). Glycolytic enzymes are important targets for anticancer 
therapy (Semenza et al. 1994; Zawacka-Pankau et al. 2011). Therefore, studying HIF 
targets gives us better understanding of the hypoxic tumor microenvironment and its 
contribution to tumor progression.   
Hypoxia and Epigenetic Regulation 
In addition to directly regulating transcription through HIFs, hypoxia can also 
modify gene expression epigenetically. It may alter DNA methylation, which directly 
influences gene expression (Cedar 1988; Chawla et al. 1996). It can also affect a series 
of post-translational modifications on histones, such as acetylation (addition of an acetyl 
group), methylation (addition of one or more methyl group), phosphorylation (addition of 
a phosphate group), ubiquitination (addition of ubiquitin tags for degradation), and 
glycosylation (addition of a carbohydrate), as reviewed by Mimura et al. (Tian and Fang 
2007; Mimura et al. 2011). Among these modifications, histone methylation is one of the 
more complex phenomena. It is involved in several fundamental processes including 
transcriptional regulation, heterochromatin formation, and DNA repair (Lachner and 
Jenuwein 2002; Margueron et al. 2005; Tian and Fang 2007).  
 10 
The Nucleosome 
DNA transcription is tightly regulated by histone modifications. As part of the 
condensation mechanism, approximately every 145-147 base pairs of DNA wraps 
around a core of histone octamer with two of each histone protein, H2A, H2B, H3, and 
H4 (Figure 1.3), to form a nucleosome (Luger et al. 1997). The protein octamer may be 
divided into two H3-H4 and two H2A-H2B histone pairs. The two H3-H4 dimers form a 
central tetramer through a 4-helix bundle between the two H3 histones. A homologous 
4-helix bundle between each H2A and H4 connects the H2A-H2B pairs with the 
tetramer to form the histone octamer (Luger et al. 1997). The unstructured N-terminal 
“tail” of each histone protein protrudes to interact with DNA. Modifications on these 
“tails” may influence DNA replication and gene transcription.  
Histone Methylation 
Histone “tails” can be methylated on the lysine (K) residue or on the arginine (R) 
residue. The arginine residues of histones can be mono- or di-methylated (symmetric or 
asymmetric). Histone arginine methylation is generally related to gene activation (Cheng 
2014). Histones can take up to three methyl groups on lysine residues H3K4, H3K9, 
H3K27, H3K36, H3K79, and H4K20 (Figure 1.3). H3K4, H3K36 and H3K79 tri-
methylation are often found in transcriptionally active regions, whereas H3K9me3/me2, 
H3K27me3 and H4K20me3 can lead to gene repression (Kouzarides 2002; Tian and 
Fang 2007; Pedersen and Helin 2010; Lu et al. 2011; Ma et al. 2011). While once 
considered to be an irreversible modification, histone lysine methylation was recently 
found to be reversible. Methyl groups can be removed by histone demethylases through  
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Figure 1.3. Schematic Diagram Showing The Basic Structure Of The Histone Core, 
With Depiction of Lysine Methylation. Green, methylated lysine residue is usually 
found in actively transcribed gene promoter regions. Red, methylated lysine residue is 
normally found in repressed gene promoters. Blue, methylated residue is often found in 
the gene body, indicating a possible role in transcription elongation. 
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enzymatic hydroxylation (Shi et al. 2004; Cloos et al. 2006; Klose et al. 2006; Tsukada 
et al. 2006; Whetstine et al. 2006; Yamane et al. 2006). 
Histone Demethylases 
Histone lysine-specific demethylases are enzymes that remove methyl groups 
from lysine residues on histone “tails”. The first lysine-specific demethylase identified 
was KDM1 (LSD1) (Shi et al. 2004). It is a FAD (flavin adenine dinucleotide)-dependent 
enzyme that uses molecular oxygen to demethylate histone H3K4 and H3K9 depending 
on its co-factor (Shi et al. 2004; Metzger et al. 2005). Another family called JmjC 
domain-containing histone demethylases are dioxygenases whose activities require 
oxygen, Fe (II) and 2-oxoglutarate (alpha-ketoglutarate) (Tsukada et al. 2006). There 
are approximately 30 different JmjC domain-containing histone demethylases 
(Pedersen and Helin 2010), among which KDM3A, KDM4B and KDM5B are well known 
HIF1 targets that are regulated by hypoxia (Beyer et al. 2008; Pollard et al. 2008; Xia et 
al. 2009; Krieg et al. 2010) (functions depicted in Figure 1.4). A few other JmjC domain-
containing proteins, including KDM3B, KDM4C, KDM5A, KDM5C, KDM7, and JMJD6, 
can also be regulated by hypoxia in certain conditions (Pollard et al. 2008; Yang et al. 
2009). These hypoxia regulated histone demethylases demonstrate a link between the 
hypoxic tumor microenvironment and epigenetic regulation, thus may play important 
roles in cancer progression.  
Histone Demethylases in Cancer 
The histone demethylases display diverse functions in cancer (Johansson et al. 
2014). Subfamily members may not always play similar roles. For example, In the 
KDM3 subfamily, KDM3A is induced by hypoxia and is overexpressed in multiple  
 14 
Figure 1.4. Schematic Diagram Showing The Enzymatic Functions Of Selected 
Hypoxia-Inducible Histone Demethylases. The N-terminus of histone H3 can be 
methylated on lysine 4, lysine 9, lysine 27 and lysine 36. H3K4 methylation is often 
found in the promoter region of actively transcribed genes, whereas H3K9 and H3K27 
are usually repressive marks. H3K36 methylation has been shown to be involved in 
elongation. KDM3A demethylates di- and mono-methylated H3K9, thus activating gene 
expression. KDM4B demethylates tri- and di-methylated H3K9 and H3K36, leading to 
activation of gene expression of inhibiting elongation, respectively. KDM5B 
demethylates tri-methylated H3K4, leading to gene repression. Once all three methyl 
groups are removed by KDM4B and KDM3A, H3K9 can further be acetylated by histone 
acetyltransferase (HAT), leading to further activation of gene expression. 
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cancers, including bladder, lung, hepatocellular, prostate, colorectal and renal cell 
carcinoma, whereas KDM3B and KDM3C have demonstrated tumor suppressing roles 
in breast cancers (Hu et al. 2001; Wolf et al. 2007; Qi et al. 2010; Uemura et al. 2010; 
Guo et al. 2011; Kim et al. 2012i; Tang et al. 2012; Yamada et al. 2012; Osawa et al. 
2013). The KDM5 and KDM6 subfamily members are mostly tumor suppressors, except 
that KDM5B and KDM6B have also demonstrated oncogenic roles (Lu et al. 1999; 
Agger et al. 2009; Barradas et al. 2009; Roesch et al. 2010; Anderton et al. 2011; Li et 
al. 2011a; Pereira et al. 2011; Ramadoss et al. 2012; Kuzbicki et al. 2013; Wouters et 
al. 2013).  
The KDM4 subfamily members are overexpressed in many cancer types and are 
generally considered oncogenes, as reviewed by several groups (Cloos et al. 2008; 
Hojfeldt et al. 2013; Johansson et al. 2014).  
The KDM4 subfamily comprises four members, KDM4A, KDM4B, KDM4C, 
KDM4D, and two potential pseudo-genes, KDM4E and KDM4F (Berry and Janknecht 
2013). KDM4A-C are more closely related and have very similar structures with a JmjN 
domain, a JmjC domain, two PHD domains and two TUDOR domains, whereas KDM4D 
only has the JmjN and JmjC domains (Johansson et al. 2014). These enzymes are able 
to demethylate H3K9me3/me2 and H3K36me3/me2, with a higher efficiency for the 
H3K9me3, which is associated with gene repression (Johansson et al. 2014). KDM4A-C 
are increased in prostate cancer and are coactivators of the androgen receptor (Berry 
and Janknecht 2013; Coffey et al. 2013). They have also been shown to be important 
regulators in estrogen receptor positive (ER+) breast cancers (Yang et al. 2010; 
Kawazu et al. 2011; Berry and Janknecht 2013). Compared to KDM4A-C, not much is 
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known about KDM4D function in cancer. More recently, a study showed that KDM4D 
was rapidly recruited to DNA damage sites in a PARP-dependent manner, thus 
promoting DNA double-strand break repair in cells (Khoury-Haddad et al. 2014). Being 
a direct HIF target and up-regulated in multiple cancer types, KDM4B shows intriguing 
importance in regulating cancer progression.  
KDM4B Function in Cancer 
KDM4B plays a significant role in tumorigenesis, driving cancer cell proliferation 
(Yang et al. 2010; Kim et al. 2012a), manipulating cell cycle (Kawazu et al. 2011; Shi et 
al. 2011; Zhu et al. 2012) and inducing chromosomal instability (Kops et al. 2005; Slee 
et al. 2011; Young et al. 2013). KDM4B is regulated by the estrogen receptor, HIF, and 
p53 (Krieg et al. 2010; Yang et al. 2010; Zheng et al. 2013). Several studies have 
shown that KDM4B is overexpressed in ER+ breast cancer and acts as a co-activator 
with ERα to regulate downstream signaling pathways (Yang et al. 2010; Kawazu et al. 
2011; Shi et al. 2011). A separate study showed that KDM4B may also regulate the 
expression of ER and FOXA1 genes, which together control the estrogen-dependent 
breast cancer phenotype (Gaughan et al. 2013). KDM4B can also regulate the 
expression of the androgen receptor (AR) in prostate cancer and act as a co-activator 
with AR in downstream signaling (Coffey et al. 2013).  
Elevated levels of KDM4B has been detected in several cancer types, including 
ER+ breast cancer (Yang et al. 2010), malignant peripheral nerve sheath tumor 
(MPNST) (Pryor et al. 2011), gastric-cancer (Li et al. 2011b), bladder cancer, lung 
cancer (Toyokawa et al. 2011), prostate cancer (Coffey et al. 2013), colorectal cancer 
(Fu et al. 2012), and osteosarcoma (Li and Dong 2015). Several KDM4B downstream 
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pathways have been identified. KDM4B promotes breast and gastric cancer proliferation 
by regulating cell cycle genes such as CCND1, CCNA1, WEE1, CDK6, and oncogenes 
such as MYB and MYC (Yang et al. 2010; Kawazu et al. 2011; Toyokawa et al. 2011; 
Kim et al. 2012a). In gastric and colon cancers, KDM4B promotes epithelial-
mesenchymal transition (EMT) by cooperating with β-catenin (Kim et al. 2012a; Zhao et 
al. 2013a). KDM4B, along with KDM4C, mediates tumorigenesis of osteosarcoma by 
inducing fibroblast growth factor 2 (FGF2) (Li and Dong 2015). KDM4B also plays a role 
in colon cancer cell apoptosis and DNA damage repair (Chen et al. 2014; Sun et al. 
2014). Besides its direct functions in cancer, KDM4B has also shown importance in 
stem cell generation and differentiation. Human KDM4B is necessary for the self-
renewal of embryonic stem cells and induces pluripotent stem cell generation (Katoh 
and Katoh 2007; Das et al. 2014). It also plays critical roles in osteogenic commitment 
of mesenchymal stem/stromal cells by promoting distal-less homeobox 2 (DLX2) 
expression (Ye et al. 2012; Qu et al. 2014). Since various steps of embryonic 
morphogenesis and wound healing involve EMT, a process also involved in early 
metastasis, these findings indicate a potential role of KDM4B in cancer cell progression 
(Hanahan and Weinberg 2000). In a study of DNA damage response, KDM4A and 
KDM4B also showed a demethylase-independent function in DNA double-strand-break 
(DSB) repair (Mallette et al. 2012). KDM4A/B binds to H4K20me2, preventing 
recruitment of 53BP1, an important factor for DSB repair. In response to DNA damage, 
RNF8 and RNF168 are recruited to the damage site, ubiquitinating and degrading 
KDM4A/B. Once KDM4A/B is degraded and released from the H4K20me2 site, 53BP1 
accumulates to perform DNA repair (Mallette et al. 2012).  
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Taken together, KDM4B is overexpressed in multiple cancers and plays an 
important role in cancer cell proliferation and invasion. However, because of the 
heterogeneity of cancer, how KDM4B functions in each cancer type may be unique. 
Detailed mechanism of how KDM4B regulates colorectal cancer is still unclear. No 
studies have been reported regarding how KDM4B functions in renal cell carcinoma or 
epithelial ovarian cancer. Systematic studies identifying the genes regulated by KDM4B 
in these cancers will reveal novel mechanisms that are specific for each cancer type, 
which may lead to more effective targeting therapy (See Chapter 2). 
Heterogeneity of Cancer 
 The heterogeneity of cancer makes it a difficult disease to treat. Not only are 
cancers generated from different organs highly distinct, but even patients with the same 
cancer type frequently have unique disease presentation and therapeutic response 
(Jamal-Hanjani et al. 2015). Within the same tumor, there are also distinct cellular 
populations with specific genetic, epigenetic, and phenotypic features (Jamal-Hanjani et 
al. 2015). The same primary tumor may contain different cellular populations that would 
generate metastatic lesions at different secondary sites, resulting in heterogeneity 
among metastases (Jamal-Hanjani et al. 2015). In addition, as cancer progresses, both 
primary and metastatic lesions can acquire new mutations and evolve independently 
with each cell division (Jamal-Hanjani et al. 2015). Therefore, finding a common 
regulatory mechanism among different cancer types may contribute significantly to 
cancer therapy efficiency by treating several cancers with the same drug.  
Colorectal Cancer 
Colorectal cancer (CRC) is the second most common cancer in males and the 
 20 
third most common cancer in females in the United States, with an estimated diagnosis 
of 71,830 men and 65,000 women and an estimated death of 26,270 men and 24,040 
women in the year of 2014 (Siegel et al. 2014a). Consumption of red meat and alcohol, 
obesity, and a history of inflammatory bowel disease are associated with a higher risk of 
CRC (Stintzing 2014). Although hereditary syndromes, such as familial adenomatous 
polyposis and hereditary non-polyposis CRC, and familial clustering are assumed to 
account for some cases of CRC, the vast majority of CRC are sporadic (about 75%) 
(Stintzing 2014). Survival rates of CRC depends on its staging, which is classified based 
on the size of the primary tumor (T stage), the involvement of lymph nodes (N stage), 
and the occurrence of distant metastases (M stage) (Stintzing 2014). The availability of 
screening programs and the development of more effective therapies have improved 
the 5-year survival rates of CRC (all stages) from about 51% in 1977 to about 65% in 
2009 when all races are taken together (Siegel et al. 2014d). Patients with Stage I or II 
tumor (Union for International Cancer Control (UICC)) have an excellent 5-year survival 
rate after surgery alone, whereas 5-year survival rates of Stage IV patients remain low 
at about 15%, even with modern improved surgical techniques and targeted therapies 
(Kopetz et al. 2009).  
Genetic alterations considered responsible for CRC development are APC, 
TP53, and KRAS mutations (Vogelstein et al. 1988). The canonical adenoma-carcinoma 
development of CRC is classified by Wnt pathway dysregulation (He et al. 1998). CRC 
may also develop through serrated polyps with early BRAF mutations (Noffsinger 2009). 
The Cancer Genome Atlas Network study with next-generation sequencing on 97 
colorectal tumors has revealed a complex network of genetic alterations leading to the 
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dysregulation of multiple pathways in CRC (Cancer Genome Atlas 2012).  
Currently, the most effective chemotherapy combination for malignant CRC 
treatment consists of a fluoropyrimidine with irinotecan or oxaliplatin (de Gramont et al. 
2000; Douillard et al. 2000; Saltz et al. 2000). However, the benefit of oxaliplatin on 
patient overall survival is restricted to younger patients (<70 years) and is not well 
established for older patients (≥70 years) (McCleary et al. 2013). Targeted therapies 
using antibodies against VEGF (bevacizumab) or EGFR (cetuximab) have recently 
shown some efficacy in combination with chemotherapies (Stintzing 2014).  
KDM4B plays important roles in CRC tumorigenesis and proliferation. Fang’s 
laboratory has discovered that induction of KDM4B by HIF-1α contributes to the 
malignant phenotype of CRC by regulating some proliferative and metastatic genes (Fu 
et al. 2012). They then went on to demonstrate that KDM4B silencing induced DNA 
damage and cell apoptosis (Chen et al. 2014; Sun et al. 2014). With a more detailed 
mechanism, Berry et al. showed that KDM4B contributed to CRC tumorigenesis by 
interacting with the key regulator in its canonical developmental pathway, β-catenin, in 
its central amino acids 353-740 (Berry et al. 2014). The complex formed by KDM4B, β-
catenin, and the DNA-binding protein TCF4, which is the main factor recruiting β-catenin 
to chromatin in the intestine, contribute to the expression of β-catenin/TCF4 
downstream oncogenes, such as JUN, MYC and Cyclin D1 (Berry et al. 2014). These 
findings indicate KDM4B may be an interesting target for CRC therapy. However, with 
only four studies published regarding the contribution of KDM4B to CRC development, 
more investigation is still necessary for a better understanding of its therapeutic 
potential. 
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Renal Cell Carcinoma 
Another cancer that is influenced by HIF signaling is renal cell carcinoma (Gudas 
et al. 2014). The estimated diagnosis of renal cell carcinoma (RCC) is 39,140 for men 
and 24,780 for women in the year of 2014. It was estimated that 8,900 men and 4,960 
women would die of RCC in 2014 (Siegel et al. 2014d). The 5-year survival rates of 
RCC has improved from 50% in 1977 to 73% in 2009 due to improved surgical 
management of the primary tumor and increased understanding of the molecular 
biology and genomics of the disease (Siegel et al. 2014d). RCC may be classified into 
three types, clear cell RCC (most common, 70% of all kidney cancers), papillary RCC 
(Type I and Type II), and chromophobe RCC (lowest-risk of developing metastases) 
(Jonasch et al. 2014). The most common genetic feature associated with clear cell RCC 
is loss or mutation of the von Hippel-Lindau (VHL) tumor suppressor gene, which is 
identified in 60-90% of sporadic cases. The loss of this protein results in stabilization of 
the HIFs, transactivating genes involved in angiogenesis, cell migration, and 
metabolism.  
Other genetic events closely associated with RCC include inactivated PBRM1, 
BAP1, and SETD2, and mutations in a variety of additional histone modifiers (KDM5A, 
ARID1A, and UTX) (Dalgliesh et al. 2010; Varela et al. 2011; Jonasch et al. 2012; Pena-
Llopis et al. 2012). RCC patient survival is also correlated to its staging. The five-year 
survival rate for patients with stage I and II RCC (American Joint Committee on Cancer 
(AJCC) staging system) is approximately 80-95%, if tumors invade the urinary collecting 
system, survival is reduced to approximately 60%, similar to the five-year survival rate 
of Stage III patients (Elmore et al. 2003; Verhoest et al. 2009). With the development of 
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targeted agents, the overall survival of Stage IV patients has increased from 10 months 
to beyond two years since the 1980s (Motzer et al. 1999; Gore and Larkin 2011). The 
current standard practice for RCC is cytoreductive nephrectomy followed by treatment 
with a chosen combination of immunotherapeutic drugs, antiangiogenic agents, and 
mTOR inhibitors (Jonasch et al. 2014). However, despite the improvement in 
therapeutic effectiveness, mortality rate of RCC remains high at an average of 37% 
(Siegel et al. 2014a). Better treatments are clearly needed.  
KDM4B overexpression has been reported in RCC cells (Beyer et al. 2008; Krieg 
et al. 2010). However, no study has ever demonstrated its function and regulatory 
mechanism in RCC. KDM4B may play important roles in RCC, yet much more study is 
needed for a thorough understanding of the potential of using KDM4B as a target for 
RCC therapy.  
HIF and Ovarian Cancer 
The Hypoxia Inducible Factor 1 (HIF1) is associated with poor prognosis of 
ovarian cancer as well as other cancer types. In response to hypoxia, HIF1 induces 
genes that promote ECM remodeling, migration and metastasis in ovarian cancer 
(Rankin et al. 2010; Horiuchi et al. 2012; Ji et al. 2013). Birner et al. showed that 
although HIF-1α overexpression alone was not a prognostic indicator, it became a 
strong prognostic marker in combination with mutation of the TP53 tumor suppressor 
(Birner et al. 2001). Lee et al. suggested that tumor hypoxia might play a role in 
conferring chemoresistance in ovarian clear cell carcinoma by HIF-1α nuclear 
localization (Lee et al. 2007). Wong et al. demonstrated a higher expression of VEGF 
and HIF-1α in epithelial ovarian cancer cells compared to normal ovarian tissue and a 
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strong correlation between the two factors, indicating high level of HIF-1 correlates to 
higher angiogenesis (Wong et al. 2003). Moreover, Osada et al determined that nuclear 
HIF-1α might represent an important biological marker in the evaluation of the prognosis 
of patients with ovarian carcinoma by showing that nuclear expression of HIF-1α was 
significantly higher in tumors of Stages III and IV (International Federation of 
Gynecology and Obstetrics (FIGO)) than in those of FIGO stages I and II (Osada et al. 
2007). Studies have also shown that the hypoxic microenvironment upgrades the stem-
like properties of ovarian cancer cells and promote ovarian CSC expansion (Liang et al. 
2012; Nozawa-Suzuki et al. 2015). Therefore, HIF-1α expression and localization 
appear to play an important role in ovarian cancer progression.  
Epithelial Ovarian Cancer  
Epithelial ovarian cancer (EOC) represents 80% of all ovarian cancers (Lengyel 
2010). It is the 10th most common cancer among women and the fifth leading cause of 
mortality, making it the most deadly of gynecologic cancers. Approximately 21,300 new 
cases of ovarian cancer will be diagnosed in 2015, accompanied by 14,180 patient 
deaths (ACS 2015). EOC is a highly heterogeneous disease, generally stratified by the 
aggressiveness of growth, with slower growing Type I tumors having better prognosis 
than more rapidly growing Type II tumors (Vang et al. 2009). Type I EOC classifies low-
grade carcinomas that develop in a stepwise manner from an atypical proliferative 
tumor through a noninvasive stage (LMP) before becoming invasive, with frequent 
mutations in KRAS, BRAF, or ERBB2 genes, whereas Type II EOC includes high-
grade, less differentiated, malignant cancers that are characterized by mutations and/or 
loss of heterzygosity in TP53 and BRCA loci (Vang et al. 2009).  
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EOC is also categorized into four pathological subtypes: serous, endometrioid, 
mucinous, and clear-cell carcinoma (Lengyel 2010). Histology of the well or moderately 
differentiated serous adenocarcinoma resembles the papillary surface epithelium of the 
fallopian tube, which is why the fallopian-tube-origin of EOC was hypothesized. 
Endometrioid carcinoma resembles endometrioid carcinomas of the uterus. The more 
well-differentiated areas of mucinous carcinomas resemble either endocervical glands 
or gastrointestinal epithelium. Clear-cell carcinoma of the ovary is a rare subtype that 
shares morphological features with both serous and endometrioid ovarian carcinoma.  
The majority of Type II EOC patients are diagnosed at an advanced FIGO stage 
(Stage III or IV), with widespread dissemination of metastatic tumors throughout the 
peritoneal cavity (Naora and Montell 2005; Vang et al. 2009; Lengyel 2010). Of the 4 
general pathological subtypes that comprise EOC, the majority of the Type II (or high 
grade) EOC are high grade serous adenocarcinoma (HGSA), which represent 70% of 
the total EOC cases (Vang et al. 2009; Lengyel 2010).  
The origin of HGSA has been debated over the years. The ovarian surface 
epithelium (OSE) has been accepted as the origin of HGSA for over 40 years. However, 
histologic characteristics of HGSA resembles that of mullerian-like tissues, whereas the 
OSE is derived from the coelomic epithelium next to the gonadal ridge. One study by 
Dr. Naora’s laboratory demonstrated that expression of the HOX genes can lead 
undifferentiated transformed mouse ovarian surface epithelial cells to undergo 
differentiation and form tumors that histologically resemble serous carcinomas, 
endometrioid-like or mucinous-like ovarian carcinomas, confirming the possibility of 
dedifferentiation and re-commitment of cancer cells during tumorigenesis (Naora and 
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Montell 2005; Lengyel 2010). Recent genomic analyses have demonstrated that the 
majority of HGSA patients have mutations in the tumor suppressor TP53, with 
significant proportions also containing mutations in BRCA1, BRCA2, and the pRB 
pathways (Cancer Genome Atlas Research 2011). Recent studies suggest that 
additional sites of origin exist and a substantial proportion of cases may arise from 
precursor lesions located in the fallopian tubal epithelium (Perets et al. 2013). This 
hypothesis is based on the detection of early lesions, namely serous tubal intraepithelial 
carcinomas (STIC), found in the fallopian tubes of both women at high-risk for 
developing serous carcinomas as well as patients with disseminated HGSCs (Perets et 
al. 2013).  
Current Therapies for HGSA 
The front-line therapy for HGSA consists of surgical debulking followed by 
treatment with platinating agents and taxol derivatives (Lengyel 2010). The initial 
response of patients to the combination of carboplatin and paclitaxel is generally 
effective, however resistant tumors typically recur within 2-4 years (Lengyel 2010). This 
rapid recurrence is caused by re-growth of residual, chemoresistant cancer cells 
residing in the peritoneal cavity. Moreover, this rapid re-establishment of tumor growth 
suggests that a process inherent to EOC progression facilitates adaptation to the 
respective stresses imposed by the metastatic process, surgery, and chemotherapy.  
Over more than 40 years, the five-year survival rate of ovarian cancer in all races 
has increased only slightly, from 36% to 44%. However, when dividing the patients into 
categories, it increased from 35% to 44% in the white population but decrease from 
42% to 36% in the black population (Siegel et al. 2014d). Therefore, a more thorough 
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understanding of the molecular mechanisms driving EOC metastasis is still very 
important for improving our ability to prevent recurrence.  
Research Objectives: KDM4B Function and Regulatory Mechanism in Cancer  
The discovery of the regulation between hypoxia and histone demethylases has 
uncovered an interesting aspect in cancer biology. As reviewed above, several histone 
demethylases, such as KDM3A, KDM4B, KDM4C, and KDM5B, are regulated by 
hypoxia. These histone demethylases have demonstrated important functions in 
promoting or suppressing tumor growth. These findings have made histone 
demethylases, especially the KDM4 subfamily interesting targets for cancer treatment. 
However, the mechanism of how KDM4B regulates tumor progression is still not clear, 
especially in CRC, RCC, and EOC. Some of the clear remaining questions include: 1. 
As a universally expressed histone demethylase, how general is the regulation by 
KDM4B in different cancer types and what are its downstream pathways in these cancer 
types? 2. Is it also overexpressed in EOC and if so, what are the functional roles of 
KDM4B in EOC? 3. How well can the JmjC domain function at low oxygen tension, 
since its enzymatic activity also requires oxygen?  
In this study, I hypothesize that KDM4B regulates general tumorigenic 
mechanisms that are shared by different cancer types as well as mechanisms 
that are specific for individual cancer types. KDM4B expression is induced by 
hypoxia in EOC cells and may regulate genes and pathways that contribute to 
EOC tumorigenesis and progression. 
To test this hypothesis, I proposed the following aims: 
Aim 1. Identify potential common and tissue-specific target genes and pathways 
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regulated by KDM4B in three cancer types. Hypothesis: KDM4B regulates distinct 
genes and pathways in different cancer types by demethylating H3K9me3/me2 in target 
gene promoters. 
a. Identify potential target genes and pathways regulated by KDM4B in three cancer 
cell lines through microarray analysis.  
b. Characterize the regulation of important KDM4B downstream targets in ovarian 
cancer progression and validate target gene expression and KDM4B demethylation 
through qRT-PCR, western blot and ChIP. 
Aim 2. Determine the functional role of KDM4B in regulating the progression of 
ovarian cancer. Hypothesis: KDM4B contributes to ovarian cancer proliferation and/or 
metastasis both in vitro and in vivo. 
a. Study the role of KDM4B in mediating cancer progression using in vitro functional 
analysis of OVCAR cell lines, including cell proliferation, migration, invasion, and 
attachment-free growth. 
b. Explore the functional role of KDM4B in vivo through intraperitoneal tumor xenograft 
growth of OVCAR cell lines in nude mice.  
Experimental findings related to Specific Aim 1 are presented in Chapter 2 and those 
associated with Specific Aim 2 are presented in Chapter 3.  
Significance of the study: KDM4B expression is induced by HIF-1α in hypoxia (Beyer et 
al. 2008; Krieg et al. 2010). Elevated levels of KDM4B have been detected in many 
cancer types, yet its regulation is poorly understood in CRC, and has never been 
demonstrated in RCC or EOC. By studying its downstream pathways in these three 
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cancers, we will have a more fundamental understanding in how KDM4B contributes to 
the progression of each cancer. By studying its functional role in ovarian cancer 
progression, we may bring better understanding of the complex network contributing to 
ovarian cancer metastasis, which is one of the main reasons for the high mortality rate 
of HGSA. Characterizing KDM4B function in HGSA metastasis will be important for the 
development of more effective therapies.  
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CHAPTER 2:  
KDM4B REGULATES DISTINCT PATHWAYS IN THREE DIFFERENT CANCERS 
AND IN DIFFERENT OXYGEN CONDITIONS 
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ABSTRACT 
Solid tumors contain hypoxic regions due to their unchecked proliferation. This 
hypoxic microenvironment induces expression of genes involved in metastasis and 
angiogenesis to promote tumor survival. The hypoxia-inducible factors (HIFs) are the 
primary regulators of the hypoxic response, inducing genes involved in important tumor 
progression pathways. The lysine (K)-specific demethylase KDM4B is a direct target of 
HIF, creating an intriguing link between the hypoxia tumor microenvironment and 
downstream gene expression beyond the direct actions of HIF stabilization. The findings 
that hypoxia-inducible KDM4B overexpression occurs in multiple cancer types suggests 
a general mechanism for KDM4B to regulate gene expression in these cancers. 
However, our current knowledge on KDM4B function in each cancer type seems to rely 
on a tissue-specific pathway. In a microarray analysis using transient knockdown of 
KDM4B, we identified a set of potential KDM4B targets with clear associations to tumor 
cell growth, migration, and metastasis. Microarray data from HCT116 colon carcinoma 
cells, SKOV3ip.1 ovarian cancer cells and RCC4 renal cell carcinoma cells identified 
numerous genes specifically regulated in each cell type, as well as 16 common targets 
shared by all three cell lines. Through Ingenuity Pathway Analysis, we found that not 
only did KDM4B regulate distinct targets in different cancer types, it also regulated 
different pathways under different oxygen conditions. In general, KDM4B regulated 
proliferation-related genes in normoxia, and migration-related genes in hypoxia. We 
have also demonstrated that KDM4B regulated these target genes by binding and 
demethylating near the promoter regions of these genes. Our findings suggest that 
KDM4B regulates pathways specific to each cancer type and tumor microenvironment 
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to support cancer cell survival.   
 
INTRODUCTION 
Hypoxia, or low oxygen tension, is a common feature of solid tumors. In 
response to hypoxia, cells manipulate their gene expression to promote survival (Chan 
and Giaccia 2007). This is not only important for normal development but is also critical 
for tumor progression. Hypoxia has been reported to contribute to metastasis, glycolysis, 
and angiogenesis, which correlates to poor prognosis and patient outcome (Chan and 
Giaccia 2007).  
A key regulator of the hypoxic gene expression pattern is the HIF family of 
transcription factors (Krieg et al. 2010). Downstream HIF targets play important roles in 
various pathways, including glycolysis, tissue remodeling, viability, proliferation, 
migration, and angiogenesis (Krieg et al. 2010). One of these known HIF targets is 
lysine (K)-specific demethylase 4B (KDM4B, also known as JMJD2B) (Krieg et al. 2010). 
KDM4B catalyzes the demethylation of H3K9me3/me2, leading to gene activation 
(Fodor et al. 2006). Its amplification has been detected in multiple cancer types, 
including ER+ breast cancer, colon cancer, renal cell carcinoma, gastric cancer, 
prostate cancer, and osteosarcoma (Beyer et al. 2008; Krieg et al. 2010; Kawazu et al. 
2011; Li et al. 2011b; Fu et al. 2012; Berry et al. 2014; Chu et al. 2014; Li and Dong 
2015). In several cancer types, KDM4B promotes cancer cell proliferation by regulating 
cell cycle genes and oncogenes, inhibiting cell apoptosis, and promoting DNA damage 
repair (Yang et al. 2010; Kawazu et al. 2011; Toyokawa et al. 2011; Kim et al. 2012a; 
Chen et al. 2014; Sun et al. 2014; Li and Dong 2015). KDM4B contributes to gastric and 
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colon cancer metastasis through the Wnt signaling pathway (Kim et al. 2012a; Zhao et 
al. 2013a). However, its molecular mechanism is still unclear in most cancer types. 
There is only limited understanding of KDM4B-dependent regulation in colon cancer. To 
date, no study has been reported regarding the function of KDM4B in ovarian cancer or 
renal cell carcinoma.  
Colorectal cancer (CRC) is the second most common cancer in males and the 
third most common cancer in females (Siegel et al. 2014a). Late-stage CRC survival 
remains low even though all-stage survival has been improved by the implementation of 
screening programs in combination with the development of more effective therapies. 
(Kopetz et al. 2009). Genetic alterations considered responsible for CRC development 
are APC, TP53, and KRAS mutations (Vogelstein et al. 1988). The most effective 
chemotherapy combination, a fluoropyrimidine with irinotecan or oxaliplatin, is not 
applicable to all patients due to its high toxicity. Therefore, novel therapies with less 
toxicity need to be developed to improve patient outcome of CRC. KDM4B has 
demonstrated some promising roles in CRC tumorigenesis through mediating 
proliferative pathways, preventing apoptosis, and promoting DNA damage repair, 
indicating it may be an interesting target for CRC therapy (Fu et al. 2012; Berry et al. 
2014; Chen et al. 2014; Sun et al. 2014).  
The most common genetic feature associated with clear cell renal cell carcinoma 
is loss or mutation of the von Hippel-Lindau (VHL) tumor suppressor gene, which leads 
to constitutively active HIF signaling. Although improvement of surgical methods and the 
application of targeted therapies have improved the survival rate of RCC, its mortality 
rate remains high and better treatments are clearly needed (Motzer et al. 1999; Gore 
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and Larkin 2011). Studies have shown that KDM4B is overexpressed in RCC, yet its 
function in RCC has not been reported at this time. Therefore, understanding the 
pathways regulated by KDM4B in RCC may lead to novel targets that would improve 
RCC therapies. 
Epithelial ovarian cancer (EOC) is the most deadly of gynecologic cancers. The 
main reason for its high mortality rate is late diagnosis, at which time the cancer has 
often disseminated throughout the peritoneal cavity and ascites fluid has developed. 
Although current surgical and chemotherapeutic approaches may successfully remove 
primary and metastatic tumors, recurrence typically occurs within five years. This poor 
prognosis of EOC has not been improved over the past 40 years (Siegel et al. 2014d). 
Therefore, a more thorough understanding of the molecular mechanisms driving EOC 
metastasis is still very important for improving our ability in preventing recurrence. 
Although little has been reported regarding KDM4B expression or function in EOC, the 
hypoxia-inducible expression of KDM4B and its contribution to other cancer types 
indicate it may also play an important role in EOC proliferation and progression.  
In this study, we identified the genes regulated by KDM4B in normoxia and 
hypoxia in the HCT116 colon carcinoma cells and SKOV3ip.1 ovarian cancer cells using 
microarray analysis and quantitative PCR. We also conducted parallel studies using 
RCC4 renal cell carcinoma cells, which do not have functional VHL thus leading to a 
“pseudo-hypoxic” phenotype. By comparing the microarray data of the three cell lines, 
we found 16 common targets, as well as many tissue-specific targets that were down-
regulated by knockdown of KDM4B. Two of the 16 common targets are LOXL2 and 
ERO1L, which are involved in ECM remodeling and VEGF secretion, respectively, 
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indicating KDM4B plays an important role in regulating target genes that are involved in 
general cancer progression (May et al. 2005; Barker et al. 2011). By comparing KDM4B 
targets in normoxia and hypoxia in each cell line, we have also found that KDM4B 
regulates distinct pathways in different oxygen conditions, where it regulates 
proliferative pathways in normoxia and metastatic pathways in hypoxia. These studies 
have defined a hypoxia-induced metastatic pathway regulated by KDM4B, confirming 
the importance of histone demethylation as a mechanism for promotion or maintenance 
of the hypoxic cancer phenotype. Understanding this regulatory mechanism of KDM4B 
in the hypoxic tumor microenvironment is therefore important for possible discovery of 
new cancer therapies.  
 
MATERIALS AND METHODS 
Cell Lines and Culture Conditions 
HCT116 and RCC4 cell lines were maintained in Dulbecco's Modified Eagle 
Medium (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal bovine 
serum (HI-FBS) and 1% Penicillin Streptomycin (Pen Strep, Invitrogen). OVCAR cell 
lines SKOV3ip.1 and OVCAR8 were maintained in RPMI-1640 (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS) and 1% pen-strep 
(Invitrogen). HCT116 and RCC4 cells were obtained from Dr. Amato Giaccia (Stanford 
University). SKOV3ip.1 cells were acquired from Dr. Erinn Rankin (Stanford University) 
with permission from Dr. Gordon Mills (M.D. Anderson Cancer Center). OVCAR8 cells 
were purchased from the NCI repository by Dr. Adam Krieg and Dr. Katherine Roby. 
Upon receipt, cells were expanded in culture to establish early passage stocks. After 
transducing with lentiviral constructs containing shRNA, as will be described later in 
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more details, cells were used for experiments within 1-2 months to minimize cell drift or 
contamination. For transient knockdown of KDM4B, SKOV3ip.1 cells were transfected 
with a pool of small interfering RNAs (siRNAs) targeting specifically to KDM4B (siK4B, 
Dharmacon siGenome Smartpool, Thermo Scientific) using Dharmafect 1 transfection 
reagent according to manufacturer’s protocol (Thermo Scientific). Scrambled siRNA 
(siCon, Dharmacon SiControl 2, Thermo Scientific) was used as the control group. For 
long-term stable knockdown of the gene, cells were transduced with lentivirus 
containing short hairpin RNA (shRNA) retroviral constructs against KDM4B (Open 
Biosystems; shKDM4B-1-puro (shK-1, TRCN0000018014) and shKDM4B-2-puro (shK-
2, TRCN0000018016)) and selected in puromycin for 2 days. For short-term hypoxia 
treatment (16-24 hours), cells were incubated in Ruskinn InVivo300 glove-box hypoxic 
incubators (Baker) in which oxygen levels were maintained at 0.5% or 2% for 16-24 
hours depending on specific experimental needs. For longer duration experiments (i.e. 
in vitro proliferation assays), cells were cultured in HeraCell150 incubators set to the 
indicated oxygen tension (Thermo Fisher Scientific, Inc.).  
QRT-PCR. 
Quantitative real-time PCR (qRT-PCR) was conducted using a modification of 
previously described methods (Krieg et al. 2010). Briefly, total RNA was isolated from 3 
× 105 cells with TRiReagent (Sigma-Aldrich) according to the manufacturer’s protocol. 
500 ng of total RNA was reverse transcribed with MMLV reverse transcriptase (Life 
Technologies) and 5 μM random primers (Life Technologies) according to the 
manufacturer’s instructions. Approximately 0.5% of each reverse transcription reaction 
mixture was added to each reaction containing 5 μL 2X SYBR green master mix (Life  
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Table 2.1. Primers Used For Qrt-PCR. 
Gene Forward (5'-3') Reverse (5'-3') 
hsKDM4B ggactgacggcaacctctac cgtcctcaaactccacctg 
hsKDM4A gccgctagaagtttcagtgag gcgtcccttggacttcttatt 
hsKDM4C aggcgccaagtgatgaag gagaggtttcgcccaagact 
hsKDM4D ggacaagcctgtaccactgag ctgcacccagaagccttg 
shCLDN12 gctgttttggaactgtcaggta ttccacacaggaaggaaagg 
shLUZP6 ggagacttggatgaggtgaaag caccttctagtgtccggttga 
shSEPT2 tctgaagctgagaaccatgc cataatgaaggtcctgggtcac 
shMMD tctttttctatctcacaatgggatt ctgaagtccatcggtgttgtt 
hsLOXL2 tgacctgctgaacctcaatg tggcacactcgtaattcttctg 
shOSMR tgtctggagaattgtgagcttg catgcagttttgataatggcttc 
shPALLD aacaccagctgtcctgcttt ggccttctttggaaatcctagt 
hsERO1L ggagacagcggcacagag caatggtttcaacatcacaggt 
shUSP6NL tgaggaggagctcccagat ttcaatttccaggtgcttttg 
shELAVL1 cctcgtggatcagactacaggt ctgggggtttatgaccattg 
shBACE2v1 tccatctacctgagagacgaga tgggctgaatgtaaagctga 
shTWSG1 gtgagcaaatgcctcattca cactccttacagcaggagcaa 
shZAKv2 tgacagagcagtccaacacc gacatgacatctctgcactgttt 
hsBRCA2 cctgatgcctgtacacctctt gcaggccgagtactgttagc 
hsSKAP2 tggagctttttctgatgagttgt tctcctacccaccagccata 
hsCEP70 gctgatcccagcctaacct cccaacgagtctcatgtctg 
hsUCK2 tccagatccccgtgtatgac acgtctgcgggatagacagt 
hsMAP3K2 tctggctcaggaagttgtcc agctctgagccctaggcatt 
hsMAP3K5 cacgtgatgacttaaaatgcttg agtcaatgatagccttccacagt 
hsMAP4K3v1 agctttggatttgcatggag ttctgacagaggtccagttacg 
hsMAP4K4v2 caggacaagctcactgctaatg tctggggtctataaaaggtgtaaag 
hsMEF2Av1 tgatgcggaatcataaaatcg tggaactgtgacagacattgaa 
hsMEF2Av2 tgaagatagtgattttattttcaaacg gtgacagacattgaaaagttctgag 
hsRAB31 gctgcagctgttatcgtgtatg ggccattacaatgttttctgg 
hsTRAF1a ctgtgcaggctgtctctctg cggcttcctgggcttatag 
hsTNFSF14 agcgaaggtctcacgaggt cggtcaagctggagttgg 
hsLPP cactgcattgaggacttcca caaagccacaatacggacag 
hsITGB8 gcattatgtcgaccaaacttca gcaacccaatcaagaatgtaact 
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hsFGFRL1 cagcctgagcgtcaactaca ctctccttccctgggctaat 
hsITGB5 ggagtttgcaaagtttcagagc tgtgcgtggagataggcttt 
hsPDGFBv1 ctggcatgcaagtgtgagac cgaatggtcacccgagttt 
hsPDGFBv2 ctggcatgcaagtgtgagac cgaatggtcacccgagttt 
hsMYD88 ttctcggaaagcgaaagc attgtctgccagcgcttc 
hsTLR3 agagttgtcatcgaatcaaattaaag aatcttccaattgcgtgaaaa 
hsTLR5 ctgtccgaacctggagaca tcctgagactataggaatctcatcac 
hsIL8 agacagcagagcacacaagc atggttccttccggtggt 
hsSMAD3 tagctcccggtagaggatca aaggctgggaaaagaagagg 
hsIRAK2 aacttgtggacctcctgtgc ccggtttccagttcaggat 
hsIL6 gatgagtacaaaagtcctgatcca ctgcagccactggttctgt 
hsIL6ST aggaccaaagatgcctcaac gaatgaagatcgggtggatg 
hsIL1β ctgtcctgcgtgttgaaaga ttgggtaatttttgggatctaca 
hsIL1R1 ccaagaagaatatgaaagtgttactca ttcttcacgttccttgcattt 
hsIL1R2 cagaaagagcttctgaaggaagac acacgggaagtggaggact 
hsIGFBP1 aatggattttatcacagcagacag ggtagacgcaccagcagagt 
hsLCN2 ctccacctcagacctgatcc acataccacttcccctggaat 
shLOXv1 ggatacggcactggctactt gacgcctggatgtagtaggg 
shLOXv2 tgggaatggcacagttgtc aaacttgctttgtggccttc 
shTGFB1 actactacgccaaggaggtcac tgcttgaacttgtcatagatttcg 
shMIR31 tctatatcagcatccacaaccttt gaccccatttttcgtggaa 
18S rRNA gcccgaagcgtttactttga tccattattcctagctgcggtatc 
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Technologies) and 50 nM forward and reverse primers specific for the genes of interest 
in a total volume of 10 uL. Real-time PCR detection was performed using an 
ABI VIIA sequence detection system using 18S rRNA as an internal control. PCR 
primers (Table 2.1) were designed using the Roche Universal Probe Library design Tool 
(http://lifescience.roche.com/shop/products/universal-probelibrary-system-assay-
design). Melt curve analysis confirmed formation of single amplicons of the expected 
size. 
Microarray Analysis.  
HCT116, SKOV3ip.1, and RCC4 cells were transiently transfected with siRNA to 
KDM4B (siK4B, Dharmacon siGenome Smartpool, Thermo Scientific) or scrambled 
siRNA (siCon, siControl 2, Thermo Scientific) for 32 hours before exposure to 21% (all 
three lines) or 0.5% oxygen (HCT116 and SKOV3ip.1 only) for an additional 16 hours. 
All experiments were performed in triplicate. A total of 100 ng RNA from each 
experimental replicate was profiled using Affymetrix GeneChip® Human Exon 1.0 ST 
exonic transcript arrays (Affymetrix). Each array consists of 1.4 million probe sets, of 
which 289,961 are core exon probes supported by putative full-length mRNA (RefSeq 
and full-length GenBank annotated alignments). These core probe sets map to 
approximately 18k genes with high confidence. These genes were the focus of the 
current study. The exon-arrays were RMA-background corrected, quantile-normalized 
and gene-level summarized using the Median Polish algorithm (Irizarry et al. 2003). The 
resulting log (base 2) transformed signal intensities (expression values) were used for 
downstream analysis. The 2-way ANOVA model: Yijk = μ + HYPOXICi + Scan Datej + 
εijk was used to calculate the significance in differential expression in genes in different 
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hypoxic conditions of ovarian cancer cells, where the intercept μ models the common 
effect of the whole experiment and ε represents the random error assumed to be 
normally and independently distributed with mean 0 and fixed variance for all 
measurements. The categorical variable ‘HYPOXIC’ models the hypoxic state of the 
cells and the categorical variable ‘Scan Date’ models the random effect attributed to the 
different days in which the experiments were performed. P-values were corrected for 
multiple-hypothesis testing by the Benjamini and Hochberg method (Benjamini and 
Hochberg 1995). The analysis was done on tissue samples obtained from biological 
triplicates. All computations were performed in the Partek Genomic suite (v 6.5, Partek 
Inc.). 
Potential KDM4B target genes were classified as those genes with >1.4 fold 
significant up- or down-regulation by siK4B knockdown (P<0.05) compared to the siCon 
transfected cells. Hypoxia-induced genes were classified as those genes with >1.4 fold 
significant up-regulation comparing siCon in hypoxia (0.5% oxygen) to siCon in 
normoxia (21% oxygen). GeneVenn (http://www.bioinformatics.org/gvenn/) was 
employed to identify overlapping expression between different oxygen tensions and 
knockdown constructs. Specific Pathways influenced by KDM4B were identified using 
Ingenuity Pathway Analysis (Ingenuity Systems). Microarray data was deposited under 
accession number GSE66894 in the NCBI’s Gene Expression Omnibus (Edgar et al. 
2002). 
ImmunoBlotting. 
Cells were lysed in SDS lysis buffer (125 mM Tris-PH6.8, 1% SDS, 10 mg/ml 
Sodium Deoxycholate, 1 mM EDTA, 5 mM DTT) with protease inhibitor cocktail (Sigma- 
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Table 2.2. Dilution information of antibodies used in Immunoblotting.  
Antigen Supplier Product NO. Discription Dilution 
KDM4B Cell Signaling 8639 Rabbit mAb 1:1,000 
KDM4A Cell Signaling 5328 Rabbit mAb 1:500 
KDM4C Novus NB110-38884 Rabbit pAb 1:1,500 
KDM4D Novus NBP1-03357 Rabbit pAb 1:2,000 
histone H3 Abcam ab1791 Rabbit pAb 1:2,000 
H3K9me3 Abcam ab8898 Rabbit pAb 1:4,000 
LCN2 R&D MAB1757 Rat mAb 1:1,000 
LOX Novus NB100-2527 Rabbit pAb 1:2,000 
α-Tubulin Thermo MS-581-PABX Mouse mAb 1:2,000 
Rabbit IgG 
(H+L) 
KPL 474-1516 Goat 
secondary Ab 
1:5,000 
Mouse IgG (γ) KPL 474-1802 Goat 
secondary Ab 
1:5,000 
Rat IgG (H+L) KPL 474-1612 Goat 
secondary Ab 
1:5,000 
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Aldrich). Following SDS-PAGE, proteins were transferred to nitrocellulose and probed 
with the indicated primary and horseradish peroxidase conjugated secondary antibodies 
(Table 2.2). Chemiluminescent signal was detected with ECL Prime reagent (GE 
Healthcare) using a Bio-Rad Molecular Imager ChemiDoc XRS+ equipped with Image 
Lab Software (Bio-Rad). 
Chromatin Immunoprecipitation Assay. 
Chromatin Immunoprecipitation was performed as described previously (Krieg et 
al. 2010), with minor modifications. Hypoxia-treated cells were fixed within the 
chambers to avoid reoxygenation. Fixed cells were then lysed with SDS lysis buffer and 
sonicated with either a Diagenode Bioruptor 300 with a chilling water bath or an Active 
Motif Q800AMS Sonicator® with an Oasis 180 Chiller with similar results. DNA 
concentration and sonication efficacy (DNA fragmented to less than 1000 bp, with an 
average length of 300 bp) from representative aliquots of input DNA were verified by 
spectrophotometry and gel electrophoresis, respectively. Depending on the antibody, 
8~50 µg of sonicated DNA per immunoprecipitation was incubated with 1~5 µg antibody 
(See Table 2.3 for more specific information). Enrichment to specific regions was 
measured using qRT-PCR. Primers to promoters and control regions were designed 
using Primer Express software (Life Technologies). See Table 2.4 for a complete list of 
primers used. Results were normalized to input to determine relative enrichment.  
Modified Histone Peptide Array. 
Histone H3K9me3 antibody specificity was tested with MODified™ Histone 
Peptide Array (ActiveMotif). Briefly, the array slide was blocked with 5% non-fat dried 
milk in TBST for one hour and then incubated with Rabbit anti-H3K9me3 antibody  
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Table 2.3. Antibody Dilution Used in Chromatin IP.  
Antigen Supplier Product NO. Discription Dilution 
KDM4B Cell Signaling 8639 Rabbit mAb 1:100 
H3K9me3 Abcam ab8898 Rabbit pAb 2-4 μg per 25 μg 
chromatin 
IgG 
Control 
Cell Signaling 3900S Rabbit mAb 560 ng/ml as control 
for KDM4B; 2 μg per 
ChIP as control for 
H3K9me3 
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Table 2.4. Primers Used in Chromatin IP. 
Gene Forward (5'-3') Reverse (5'-3') Genomic coordinates 
ERO1L-1 ggctagtgcccactgtattagaca cctcacttctctaggcctgtttct chr14:53,163,046-53,163,127 
ERO1L-2 cacctctgtgccgctgtct gccggagctgcaatgg chr14:53,162,096-53,162,211 
LOXL2-1 agcgcctgcgtaaaagttgt gctacagctgatcccaatcttga chr8:23,260,663-23,260,733 
LOXL2-2 tgccttgtccacctcctatcc aacactttcattcggcagcttt chr8:23,261,969-23,262,053 
PDGFB-1 gagccctccgccttaacc cagccaggcgcaggaa chr22:39,638,710-39,638,763 
PDGFB-2 cctggcactcgggagctt tccaggttgaggctagatgga chr22:39,641,397-39,641,470 
PDGFB-3 ggaagctggatggcaaagg tctggcctcagcacacttctt chr22:39,637,081-39,637,147 
LCN2 aagtgtttccgcaggagttg gggatctagggtgggttgat chr9:130,911,623-130,911,702 
LOX actgagcgcaggaacttctc cactggttccaagctggcta chr5:121,413,216-121,413,314 
DESERT-
C16D8 
gagcaagcagaccctaatgc ctgtccactcaggagccttc chr16:62,316,298-62,316,449  
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(Abcam; Cat# ab8898) for two hours at room temperature. The slide was then incubated 
with secondary antibody (KPL; Cat# 474-1516) for 30 minutes and detected with the 
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life 
Sciences). Antibody specificity was analyzed with manufacturer’s Array Analyze 
Software (Active Motif). 
RESULTS 
KDM4B Regulates Common and Tissue-Specific Targets in Three Cancer Types 
KDM4B has demonstrated functional contribution in multiple cancer types, as reviewed 
in Chapter 1. To determine whether the KDM4B-dependent regulation is general for 
multiple cancer types or specific for each cancer, we identified genes regulated by 
KDM4B in SKOV3ip.1 ovarian carcinoma, HCT116 colon carcinoma, and RCC4 renal 
cell carcinoma cell lines. SKOV3ip.1 is an epithelial ovarian cancer cell line sub-cultured 
from ascites cells generated by intra-peritoneal injection of SKOV3 parental cells, which 
do not express p53 (Yu et al. 1993; O'Connor et al. 1997). HCT116 is an epithelial colon 
carcinoma cell line that expresses wild type p53 (el-Deiry et al. 1994). RCC4 is a VHL-
deficient renal cell carcinoma cell line that displays a “pseudo-hypoxia” phenotype 
(Maxwell et al. 1999). Cells were transiently transfected with siRNA to KDM4B (siK4B) 
or an irrelevant control (siCon), achieving robust knockdown in both standard growth 
condition (21% oxygen or normoxia) and hypoxia (0.5% oxygen) in all cell lines tested 
(Fig. 2.1A). RCC4 cells were only tested in normoxic condition since HIF-1α is 
constitutively active due to its VHL-deficiency. Genes dependent on KDM4B in 
SKOV3ip.1 and HCT116 cells in 0.5% oxygen and in RCC4 cells in 21% were identified 
by microarray analysis (fold change of -1.4 or less, relative to siCon transfected cells in  
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Figure 2.1. Identification of common KDM4B target genes in HCT116 colon 
carcinoma, SKOV3ip.1 ovarian cancer and RCC4 renal cell carcinoma cell lines. A, 
HCT116 colon carcinoma, SKOV3ip.1 ovarian cancer, and RCC4 renal cell carcinoma 
cells were transfected with siRNA to KDM4B (siK4B) and control siRNA (siCon). 
HCT116 and SKOV3ip.1 cells were exposed to normoxia (21% O2) and hypoxia (0.5% 
O2) for 16 hours, whereas RCC4 cells were only exposed to normoxia (21% O2). QPCR 
with primers to KDM4B confirmed knockdown in all three cell lines. Data represents 
average fold change ± SEM from three independent experiments measured in triplicate. 
*, p<0.05, determined by Two-tailed Paired Student’s T Test. B, Venn Diagram showing 
the number of genes overlapped in the three cell lines and those that are distinct for 
each cancer type. RNA was profiled using Affymetrix Human Exon ST1.0 arrays in the 
KUMC Microarray Facility and analyzed in the KUMC Bioinformatics core using Partek 
RMA analysis. Genes significantly decreased in expression with siK4B (absolute 
decrease of or greater than 1.4 fold, p<0.05) in HCT116 cells under hypoxia are 
depicted in dark gray (top left), genes significantly decreased in expression with siK4B 
in SKOV3ip.1 cells under hypoxia are shown in light gray (top right), and genes 
significantly decreased in expression with siK4B in RCC4 cells are shown in white 
(bottom). The numbers of genes in the overlap regions are depicted.  
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either condition, P < 0.05) and compared by GeneVenn. A total of 932, 276, and 1,128 
gene probes were dependent on KDM4B in SKOV3ip.1, HCT116, and RCC4, 
respectively. Among these gene probes, only 17 genes were commonly regulated in all 
three cell lines (Fig. 2.1B, Table 2.5), among which two probes represent the same 
gene, SEPT2. A majority of these targets are involved in tumorigenesis- and/or 
metastasis-related pathways (Table 2.5). For example, genes like claudin-12 (CLDN12), 
leucine zipper protein 6 (LUZP6/MPD6), septin-2 (SEPT2), monocyte to macrophage 
differentiation-associated (MMD), and DENN/MADD domain containing 5A (DENND5A) 
are involved in tumorigenesis and proliferation (Wang et al. 2006; Xiong et al. 2006; 
Grone et al. 2007; Morita et al. 2008; Li and He 2014), whereas lysyl oxidase-like 2 
(LOXL2), oncostatin M receptor (OSMR), palladin (PALLD), endoplasmic reticulum 
oxidoreductin 1-like (ERO1L), and USP6 N-terminal-like protein (USP6NL/RN-tre) play 
important roles in cancer metastasis and are usually associated with malignancy and 
poor prognosis (Goicoechea et al. 2009; Barker et al. 2011; Fossey et al. 2011; Kutomi 
et al. 2013; Palamidessi et al. 2013). Embryonic Lethal, Abnormal Vision, Drosophila-
Like 1 (ELAVL1/HuR) promotes cancer cell resistance to chemotherapy drugs or 
apoptosis by binding to the 3’-UTR of WEE1 or caspase 2L mRNA, respectively (Licata 
et al. 2010; Lal et al. 2014; Winkler et al. 2014). ZAK, ZDHHC2 and DAZAP2 appear to 
have tumor suppressing potential. For example, ZAK plays a role in leading cells to cell 
cycle arrest (Yang 2002). Reduced ZDHHC2 expression is associated with lymph node 
metastasis and predicts a poor prognosis of gastric cancer (Yan et al. 2013). Not much 
is known about the role of DAZAP2 in cancer but it has been shown to be 
downregulated in human multiple myeloma (Shi et al. 2007; Luo et al. 2012).  
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Table 2.5. List of the 16 Genes Commonly Regulated by KDM4B in Three Cancer 
Cell Lines. 
Gene 
Symbol 
Description Fold change Cell process Citation 
CRC EOC RCC 
CLDN12 claudin 12 -1.52 -2.24 -1.7 Tumorigenesis (Grone et al. 
2007) 
LUZP6 myotrophin; 
leucine zipper 
protein 6 
-1.53 -1.44 -1.49 Myeloproliferative 
disease-
associated 
antigen 
(Xiong et al. 
2006) 
SEPT2 septin 2 -1.46 -1.97 -2.24 Cell division, cell 
proliferation; 
carcinogenesis  
(Yu et al. 2009; 
Liu et al. 2010) 
MMD monocyte to 
macrophage 
differentiation
-associated 
-1.63 -4.4 -5.49 Macrophage 
maturation, Erk 
and Akt 
activation 
(Liu et al. 
2012) 
LOXL2 lysyl oxidase-
like 2 
-1.62 -3.18 -3.28 Cell migration, 
metastasis 
(Barker et al. 
2011) 
OSMR oncostatin M 
receptor 
-1.52 -1.61 -1.73 Angiogenesis, 
cell migration 
(Fossey et al. 
2011) 
PALLD palladin, 
cytoskeletal 
associated 
protein 
-1.58 -1.47 -1.78 Cytoskeletal 
remodeling, 
metastasis 
(Goicoechea et 
al. 2009) 
ERO1L ERO1-like (S. 
cerevisiae) 
-1.43 -3.38 -2.85 Disulfide bond 
formation in ER 
(Cabibbo et al. 
2000; May et 
al. 2005) 
USP6NL USP6 N-
terminal like 
-1.49 -1.48 -1.82 Focal adhesion 
remodeling  
(Palamidessi 
et al. 2013) 
ELAV1 embryonic 
lethal, 
abnormal 
vision, 
Drosophila-
like 1 (Hu 
-1.45 -1.6 -1.63 Regulation of 
RNA stability 
(Licata et al. 
2010; Lal et al. 
2014; Winkler 
et al. 2014) 
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antigen R) 
BACE2 beta-site 
APP-cleaving 
enzyme 2 
-1.4 -1.81 -1.8 Cleaves Amyloid-
beta-precursor 
protein 
(Farzan et al. 
2000; Xie et al. 
2007) 
TWSG1 twisted 
gastrulation 
homolog 1 
(Drosophila) 
-1.45 -1.94 -2.39 BMP agonist (Oelgeschlager 
et al. 2000) 
ZAK sterile alpha 
motif and 
leucine zipper 
containing 
kinase AZK 
-1.54 -1.65 -1.64 Cell cycle 
checkpoint, 
proapoptotic  
(Yang 2002) 
ZDHHC2 zinc finger, 
DHHC-type 
containing 2 
-1.49 -1.53 -2.06 Palmitoyl-
acyltransferase, 
tumor suppressor 
(Zhang et al. 
2008) 
DENND5A  DENN/MADD 
domain 
containing 5A 
-1.4 -1.62 -2.6 Intracellular 
trafficking and 
cell cycle 
progression 
(Li et al. 2014) 
DAZAP2 DAZ 
associated 
protein 2 
-1.52 -2.5 -3.73 TCF4 binding 
factor and 
coactivator; 
downregulated in 
multiple myeloma 
(Lukas et al. 
2009; Luo et 
al. 2012) 
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QPCR results showed that knocking down KDM4B significantly impaired expression of 
these targets, confirming the accuracy of Microarray analysis (Figure 2.3-2.6). Two 
independent experiments were conducted with HCT116 cells to achieve better hypoxic 
induction (KDM4B knockdown from HCT116 experiments were validated in Figure 2.2). 
Although the decrease in the expression of some targets by siK4B was not statistically 
significant, which was most likely due to small sample size of the experimental 
replicates and low expression level of some target genes, the trend of regulation of 
these genes by KDM4B was consistent (Figure 2.3-2.6). SKOV3ip.1 and RCC4 seemed 
to share more KDM4B targets (113), whereas HCT116 shared fewer common targets 
with each line (44 with RCC4 and only 9 with SKOV3ip.1). The majority of targets 
regulated by KDM4B in each cell line were specific for the line (206 for HCT116, 773 for 
SKOV3ip.1, and 934 for RCC4), indicating the primary regulatory mechanisms mediated 
by KDM4B in different cancers are distinct.  
KDM4B Regulates Distinct Pathways in Different Oxygen Conditions in HCT116 
and SKOV3ip.1 
By comparing KDM4B targets in normoxia and hypoxia, we found that less than 
10% of these targets overlapped in HCT116 cells and less than 15% overlapped in 
SKOV3ip.1 cells (Figure 2.7 A-B). KDM4B regulated only 3% and 11% of the hypoxia-
inducible genes in HCT116 and SKOV3ip.1, respectively (Figure 2.7 C-D). A majority of 
KDM4B targets in hypoxia were not hypoxia-induced, suggesting KDM4B regulated 
genes independent from HIF or there might be other compensatory or inhibitory 
regulators involved.  
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Figure 2.2. KDM4B expression in HCT116 cells. HCT116 cells were transfected with 
siRNA to KDM4B (siK4B) and control siRNA (siCon). Cells were exposed to normoxia 
(21% O2) and hypoxia (0.5% O2) for 16 hours. QPCR with primers to KDM4B confirmed 
knockdown. Data represents average fold change ± SEM from two independent 
experiments measured in triplicate. *, p<0.05, determined by Two-tailed Paired 
Student’s T Test. 
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Figure 2.3. Common KDM4B targets in the SKOV3ip.1, HCT116 and RCC4 that are 
involved in tumorigenesis and proliferation pathways. A, SKOV3ip.1 RNA samples 
were used for QPCR. Data represent average fold change ± SEM from three 
independent experiments measured in triplicate. *, P<0.05, determined by Two-tailed 
Paired Student’s T Test. B, HCT116 RNA samples were used for QPCR. Data 
represent average fold change ± SEM from two independent experiments measured in 
triplicate. *, P<0.05, determined by Two-tailed Paired Student’s T Test. C, RCC4 RNA 
samples were used for QPCR. Data represent average fold change ± SEM from three 
independent experiments measured in triplicate. *, P<0.05, determined by Two-tailed 
Paired Student’s T Test. 
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Figure 2.4. Common KDM4B Targets in the SKOV3ip.1, HCT116 and RCC4 that are 
involved in migration and metastasis pathways. A, SKOV3ip.1 RNA samples were 
used for QPCR. Data represent average fold change ± SEM from three independent 
experiments measured in triplicate. *, P<0.05, determined by Two-tailed Paired 
Student’s T Test. B, HCT116 RNA samples were used for QPCR. Data represent 
average fold change ± SEM from two independent experiments measured in triplicate. *, 
P<0.05, determined by Two-tailed Paired Student’s T Test. C, RCC4 RNA samples 
were used for QPCR. Data represent average fold change ± SEM from three 
independent experiments measured in triplicate. *, P<0.05, determined by Two-tailed 
Paired Student’s T Test.  
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Figure 2.5. Common KDM4B Targets in the SKOV3ip.1, HCT116 and RCC4 that are 
involved in protein folding and processing and RNA processing. A, SKOV3ip.1 
RNA samples were used for QPCR. Data represent average fold change ± SEM from 
three independent experiments measured in triplicate. *, P<0.05, determined by Two-
tailed Paired Student’s T Test. B, HCT116 RNA samples were used for QPCR. Data 
represent average fold change ± SEM from two independent experiments measured in 
triplicate. *, P<0.05, determined by Two-tailed Paired Student’s T Test. C, RCC4 RNA 
samples were used for QPCR. Data represent average fold change ± SEM from three 
independent experiments measured in triplicate. *, P<0.05, determined by Two-tailed 
Paired Student’s T Test.  
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Figure 2.6. Common KDM4B Targets in the SKOV3ip.1, HCT116 and RCC4 that are 
involved in amyloid protein precursor cleavage, ion metabolism, and apoptosis. A, 
SKOV3ip.1 RNA samples were used for QPCR. Data represent average fold change ± 
SEM from three independent experiments measured in triplicate. *, P<0.05, determined 
by Two-tailed Paired Student’s T Test. B, HCT116 RNA samples were used for QPCR. 
Data represent average fold change ± SEM from two independent experiments 
measured in triplicate. *, P<0.05, determined by Two-tailed Paired Student’s T Test. C, 
RCC4 RNA samples were used for QPCR. Data represent average fold change ± SEM 
from three independent experiments measured in triplicate. *, P<0.05, determined by 
Two-tailed Paired Student’s T Test. 
 61 
 
 62 
Figure 2.7. Identification of KDM4B target genes in HCT116 colon carcinoma cells 
and in SKOV3ip.1 ovarian cancer cells. A, Venn diagram showing the overlap 
between genes down-regulated greater than 1.4 fold by siK4B in normoxia (left circle) 
and hypoxia (right circle) in HCT116 colon carcinoma cells. B, Venn diagram showing 
the overlap between genes down-regulated greater than 1.4 fold by siK4B in normoxia 
(left circle) and hypoxia (right circle) in SKOV3ip.1 cells. C, Venn diagram showing the 
overlap between genes induced greater than 1.4 fold in hypoxia (left circle) and genes 
down-regulated greater than 1.4 fold by siK4B in hypoxia (right circle) in HCT116 colon 
carcinoma cells. D, Venn diagram showing the overlap between genes induced greater 
than 1.4 fold in hypoxia (left circle) and genes down-regulated greater than 1.4 fold by 
siK4B in hypoxia (right circle) in SKOV3ip.1 ovarian cancer cells.  
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Ingenuity Pathway Analysis determined that the predominant pathways regulated 
by KDM4B in each oxygen condition were distinct in SKOV3ip.1 cells (Table 2.6-2.7). In 
atmospheric oxygen, genes involved in cancer, cell cycle (including DNA replication, 
recombination, and repair), and cell death pathways were influenced most significantly 
by KDM4B. In contrast, genes involved in inflammatory response, cellular development, 
and cellular movement were predominantly represented in hypoxia, implying a role in 
metastasis. Cell proliferation and metastasis are known to be the most critical pathways 
manipulated in cancer to promote survival during early (usually without hypoxic stress) 
and late (promoted by HIF-signaling) stages of cancer development, respectively. By 
regulating OVCAR cell proliferation in normoxia and metastasis in hypoxia, KDM4B may 
play crucial roles in promoting ovarian cancer progression. 
Similar differential regulation by KDM4B was also detected in HCT116 cells, 
although to less extent. In HCT116 cells, KDM4B regulated cellular assembly, cellular 
movement and cellular development in both normoxia and hypoxia (Table 2.6). 
However, the effect was more significant and more genes were involved in these 
pathways in hypoxia. Moreover, cell morphology and cell-to-cell signaling pathways 
were also regulated by KDM4B in hypoxia, whereas cellular function and maintenance 
and molecular transport were influenced in normoxia. Cancer was still among the top 
diseases influence by KDM4B in normoxia, whereas metabolic disease and endocrine 
system disorders were the major diseases affected in hypoxia (Table 2.7). These results 
suggested a KDM4B-dependent metastatic phenotype in hypoxia and cell maintenance 
in normoxia in HCT116 cells.  
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Table 2.6. Molecular and Cellular Functions Regulated by KDM4B in Normoxia or 
Hypoxia in SKOV3ip.1, HCT116, and RCC4 Cells. 
Cell Line/O2 
Condition Name P-value # Molecules 
SKOV3ip.1 
Normoxia 
Cell Cycle   7.00E-15 - 8.16E-04 239 
Cellular Assembly and Organization   6.70E-14 - 7.94E-04 197 
DNA Replication, Recombination, and 
Repair  6.70E-14 - 8.16E-04 182 
Cell Death  8.00E-14 - 8.19E-04 353 
Post-Translational Modification 1.29E-08 - 7.92E-04 153 
SKOV3ip.1 
Hypoxia 
Cellular Movement 2.51E-10 - 5.57E-03 77 
Cellular Development 8.92E-10 - 4.14E-03 99 
Cell Death 4.59E-07 - 5.57E-03 100 
Cell-To-Cell Signaling and Interaction 8.13E-07 - 5.57E-03 78 
Antigen Presentation 1.00E-06 - 4.46E-03 50 
HCT116 
Normoxia 
Cellular Assembly and Organization   1.63E-04 - 4.55E-02 14 
Cellular Function and Maintenance   1.63E-04 - 3.63E-02 9 
Molecular Transport   1.63E-04 - 4.79E-02 9 
Cellular Movement   1.81E-04 - 4.79E-02 13 
Cellular Development   2.62E-04 - 4.32E-02 15 
HCT116 
Hypoxia 
Cellular Assembly and Organization  8.77E-07 - 9.89E-03 39 
Cellular Movement   2.93E-06 - 9.89E-03 34 
Cell Morphology   3.39E-06 - 9.89E-03 27 
Cell-To-Cell Signaling and Interaction  3.00E-05 - 9.89E-03 28 
Cellular Development   5.03E-05 - 9.89E-03 48 
RCC4 
Pseudo-
Hypoxia 
Cell Cycle  2.23E-14 - 3.05E-03 148 
Cellular Assembly and Organization  4.66E-10 - 2.94E-03 143 
DNA Replication, Recombination, and 
Repair  4.66E-10 - 2.11E-03 100 
Cell Death  5.88E-10 - 3.00E-03 228 
Cellular Growth and Proliferation  1.38E-09 - 3.13E-03 247 
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Table 2.7. Disease and Disorders Regulated by KDM4B in Different Oxygen 
Conditions in SKOV3ip.1, HCT116, and RCC4 Cells. 
Cell Line/O2 
Condition Name   P-value # Molecules 
SKOV3ip.1 
Normoxia 
Cancer 6.37E-20 - 7.63E-04 496 
Gastrointestinal Disease 4.81E-16 - 8.16E-04 422 
Hematological Disease 5.56E-13 - 7.63E-04 141 
Genetic Disorder 2.03E-11 - 7.94E-04 249 
Infectious Disease 9.82E-11 - 6.64E-04 187 
SKOV3ip.1 
Hypoxia 
Inflammatory Response 1.64E-12 - 5.57E-03 97 
Inflammatory Disease 5.53E-05 - 4.52E-03 90 
Renal and Urological Disease  5.53E-05 - 3.50E-03 29 
Respiratory Disease  1.46E-04 - 2.11E-03 22 
Hematological Disease 1.48E-04 - 3.26E-03 8 
HCT116 
Normoxia 
Neurological Disease 5.84E-05 - 4.56E-02 17 
Cancer 9.25E-05 - 4.09E-02 20 
Renal and Urological Disease   9.25E-05 - 4.56E-02 5 
Cardiovascular Disease   1.27E-04 - 4.56E-02 11 
Gastrointestinal Disease  2.32E-04 - 3.07E-02 12 
HCT116 
Hypoxia 
Neurological Disease  1.05E-06 - 9.89E-03 61 
Metabolic Disease  1.73E-06 - 9.89E-03 57 
Endocrine System Disorders 3.68E-06 - 9.89E-03 52 
Gastrointestinal Disease  3.68E-06 - 9.89E-03 81 
Genetic Disorder   3.68E-06 - 9.89E-03 108 
RCC4 
Pseudo-
Hypoxia 
Cancer 4.02E-21 - 3.13E-03 305 
Gastrointestinal Disease 6.68E-14 - 2.98E-03 303 
Reproductive System Disease 6.33E-11 - 3.13E-03 184 
Genetic Disorder 2.17E-10 - 2.98E-03 271 
Hematological Disease 6.43E-07 - 2.49E-03 84 
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KDM4B Differentially Regulates Gene Expression in Atmospheric and Hypoxic 
Growth Conditions in Ovarian Cancer Cell Lines 
Since the differential regulation of pathways by KDM4B in different oxygen 
conditions was most obvious in SKOV3ip.1 cells, further studies continued with this cell 
line to demonstrate the potential mechanism of this regulation. Immunoblot showed that 
siRNA robustly knocked down KDM4B protein expression in SKOV3ip.1 cells and global 
H3K9me3 level was not influence by KDM4B knockdown (Figure 2.8). The expression 
of targets from the proliferation, inflammatory response, and metastasis networks were 
validated by QPCR (Figure 2.9). Proliferative genes like BRCA2, CEP70, SKAP2, 
MAP4K3 and MAP4K4 displayed robust dependence on KDM4B in normoxic conditions, 
with lesser effect in hypoxia (0.5% siCon) (Figure 2.9A). Many inflammation-associated 
genes exhibited robust dependence on KDM4B in both conditions, (SMAD3, IL-1B, IL-8, 
IL-6ST, Figure 2.9B). Similarly, several genes associated with metastatic pathways 
(LOXL2, ERO1L, PDGFB, TRAF1a, FGFRL1, LPP, ITGB5, Figure 2.9C) were also 
dependent on KDM4B in both oxygen tensions.  
In order to establish a more robust experimental system for the study of KDM4B 
in functional and mechanistic assays, SKOV3ip.1 and OVCAR8 cells were stably 
transduced with two shRNA constructs targeting KDM4B (shK-1 and shK-2, see 
Materials and Methods for description). SKOV3ip.1 is an EOC cell line sub-cultured 
from ascites cells of an intra-peritoneal xenograft model injected with SKOV3 parental 
cells (Yoneda et al. 1998). It is a commonly used ovarian cancer model for in vitro and 
in vivo studies. OVCAR8 is an undifferentiated ovarian carcinoma that lacks p53 
(Hamilton et al. 1984). Compared to an irrelevant control shRNA (shGFP), shK-1 and  
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Figure 2.8. H3K9 tri-methylation in SKOV3ip.1 transfected with siK4B. SKOV3ip.1 
cells were transfected with siRNA to KDM4B (siK4B) and control siRNA (siCon). Cells 
were exposed to normoxia (21% O2) and hypoxia (0.5% O2) for 16 hours. Antibodies 
were used to validate KDM4B expression and HeK9 trimethylation level. Tubulin serves 
as control for protein loading of the KDM4B blot. Histone H3 serves as controls for 
protein loading of H3K9me3, probed on a separate blot loaded with the same aliquots of 
protein samples. Images were taken from one representative experiment. 
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Figure 2.9. KDM4B regulates proliferative, inflammatory, and metastatic genes in 
SKOV3ip.1 cells. A, Quantitative RT-PCR validation of selected proliferation-
associated genes regulated by KDM4B.  B, Quantitative RT-PCR validation of 
inflammation-associated genes regulated by KDM4B.  C, Quantitative RT-PCR 
validation of metastasis-associated genes regulated by KDM4B. Data in represent 
mean Fold Change ± S.E.M. normalized to 18S rRNA, calculated relative to siCon in 
21% O2 (black bars). Results were averaged from three independent experiments, 
measured in triplicate. Significance of differences was calculated using two-tailed paired 
Student’s T-test (!, P<0.05 for siK4B compared to siCon,; #, P<0.05 for hypoxia 
compared to normoxia) or two-way ANOVA (*, P<0.05). 
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shK-2 significantly suppressed expression of KDM4B protein and RNA in 21% and 0.5% 
oxygen in both cell lines (Figure 2.10). Most importantly, hypoxic induction was robustly 
attenuated to levels less than or equivalent to the shGFP control at 21%.  
Two other KDM4 family members, KDM4A and KDM4C, are structurally similar to 
KDM4B (Whetstine et al. 2006; Berry and Janknecht 2013), and a third family member 
KDM4D has been shown to have overlapping functions in other systems (Iwamori et al. 
2011). Expression of these other members of the KDM4 family was measured by qRT-
PCR and immunoblotting to determine if any compensatory expression was induced 
following suppression of KDM4B (Figure 2.10). Our qRT-PCR results suggested that 
there was no biologically significant change in KDM4A and KDM4C expression at the 
mRNA or protein level with suppression of KDM4B. However, KDM4D mRNA and 
protein were both upregulated in cells expressing shRNA to KDM4B, particularly in 
OVCAR8 cells transduced with construct shK-1. Similar to what has been reported in 
other systems (Beyer et al. 2008), knockdown of KDM4B did not increase H3K9 
trimethylation in whole cell extracts (Fig. 2.8 and 2.11, anti-H3K9me3 antibody 
specificity was demonstrated in Figure 2.12). There may have been a decrease in 
methylation, indicating that any regulation of target genes by demethylation is through 
specific recruitment to regulatory regions and not global changes in the epigenetic 
environment.  
The hypoxic induction of the putative target gene platelet derived growth factor 
beta (PDGFB, a potent angiogenic, lymphangiogenic, and transformative factor (Schito 
et al. 2012)) was attenuated by approximately 30% in hypoxic SKOV3ip.1 cells 
expressing shRNA to KDM4B Figure 2.13B), with a decrease of 50% in OVCAR8 cells  
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Figure 2.10. Expression of KDM4 subfamily members in SKOV3ip.1 and OVCAR8 
cells expressing shRNA to KDM4B. A, Quantitative RT-PCR measurement of KDM4A, 
KDM4B, KDM4C, and KDM4D in SKOV3ip.1 cells expressing shRNA to KDM4B (shK-1, 
dark grey and shK-2, light grey) in 21%, 2%, and 0.5% oxygen. Data represent mean 
three independent experiments ± S.E.M measured in triplicate, normalized to shGFP 
control at 21% oxygen. *, P<0.05, determined by two-tailed paired Student’s t-test. B. 
Immunoblot of KDM4B, KDM4A, KDM4C, and KDM4D in SKOV3ip.1 cells in Panel A. 
Tubulin serves as a loading control. C, Quantitative RT-PCR measurement of KDM4A, 
KDM4B, KDM4C, and KDM4D RNA in OVCAR8 cells expressing shRNA to KDM4B as 
in Panel A. D, Immunoblot of KDM4B, KDM4A, KDM4C, and KDM4D in OVCAR8 cells, 
as in Panel B. 
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Figure 2.11. H3K9me3 Level in SKOV3ip.1 and OVCAR8 ovarian cancer cell lines. 
A. Immunoblot measurement of KDM4B and H3K9me3 in SKOV3ip.1 cells expressing 
shRNA targeting KDM4B (shK-1 and shK-2) or GFP (control) in 21%, 2%, and 0.5% O2. 
Tubulin and histone H3 serve as loading controls. B. Immunoblot of OVCAR8 cells, 
treated as in Panel A.  
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Figure 2.12. Modified Histone Peptide Array. A, Specificity Plot demonstrating that 
the H3K9me3 antibody (Abcam ab8898) used for immunoblotting and ChIP was more 
specific for H3K9me3 than other modifications, including H3K27me3. B, Reactivity Plot 
for Abcam ab8898, demonstrating preferential reactivity with H3K9me3. Data was 
analyzed and figures generated with Array Analyze Software (Active Motif).  
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Figure 2.13. Expression of KDM4 target genes in SKOV3ip.1 and OVCAR8 cells 
expressing shRNA to KDM4B. A-F, Quantitative RT-PCR measurement of KDM4B 
target genes in SKOV3ip.1 cells expressing shRNA to KDM4B (shK-1, dark grey and 
shK-2, light grey) in 21%, 2%, and 0.5% oxygen. Data represent mean ± S.E.M, 
normalized to shGFP control at 21% oxygen. Results were averaged from two to four 
independent experiments, measured in triplicate. *, P<0.05, determined by two-tailed 
paired Student’s t-test. G-I, Quantitative RT-PCR measurement of KDM4B target genes 
in OVCAR8 cells expressing shRNA to KDM4B (shK-1, dark grey and shK-2, light grey) 
in 21%, 2%, and 0.5% oxygen. Data represent mean ± S.E.M, normalized to shGFP 
control at 21% oxygen. Results were averaged from four independent experiments, 
measured in triplicate. *, P<0.05, determined by two-tailed paired Student’s t-test. 
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in all oxygen tensions tested (Figure 2.13H). Other candidate genes from the metastatic 
(LOX and LOXL2) and inflammatory (IL-1R2) pathways also displayed attenuated 
induction with KDM4B knockdown in SKOV3ip.1 cells, although with less significance, 
which may be due to compensation from KDM4D (Figure 2.13D-F). KDM4B also 
regulates normoxic and hypoxic expression of genes not induced under hypoxia, such 
as LCN2 in SKOV3ip.1 cells (Figure 2.13C) and IGFBP1 in OVCAR8 cells (Figure 2.13I).  
Combined, this data suggest that KDM4B preferentially regulates distinct 
functions in different oxygen tensions, providing multiple avenues to affect EOC tumor 
growth.  
KDM4B Binds and Demethylates Regulatory Regions of Target Genes to Promote 
Expression 
KDM4B is primarily thought to regulate gene expression by demethylating tri- and 
di-methylated lysine 9 of histone H3 (H3K9me3 and H3K9me2), altering the chromatin 
environment to favor transcription by removing a modification associated with 
repression (Mosammaparast and Shi 2010). In order to investigate this mechanism in 
EOC cells, SKOV3ip.1-shGFP and SKOV3ip.1-shK-2 cells were exposed to 21% and 
0.5% oxygen for 16 hours, and the formaldehyde-fixed cells processed for chromatin 
immunoprecipitation (ChIP) using antibodies against KDM4B and H3K9me3. 
In SKOV3ip.1-shGFP cells, KDM4B was localized to regions near the 
transcription start sites of PDGFB, LCN2, LOX and LOXL2, which have been shown to 
play important roles in cancer metastasis (Figure 2.14). PDGFB is one of the secreted 
factors involved in promoting the recruitment of pericytes along the vascular endothelial 
cells, a process required in tumor angiogenesis (Chantrain et al. 2006). Studies have  
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Figure 2.14. Chromatin IP demonstrating that KDM4B binds and demethylates its 
target gene promoters. A, Map of ChIP-qPCR primers sets used to measure KDM4B 
association and demethylation at or near target gene promoters. B, ChIP assay for 
KDM4B near target gene promoters in SKOV3ip.1 cells treated with normoxia (21% 
oxygen) or hypoxia (0.5% oxygen) for 16 hours. QRT-PCR results are shown as fold 
change relative to 21% shGFP control. Data represent mean ± S.E.M of three 
independent experiments measured in triplicate. *, P<0.05, determined by two-tailed 
paired Student’s t-test. C, ChIP qPCR analysis of H3K9me3 on selected promoter 
regions of target genes following shRNA to KDM4B (shK-2, light grey bars) compared to 
shGFP control (black bars). Chromatin was immunoprecipitated with anti-H3K9me3 or 
anti-IgG antibodies, and the DNA was analyzed by qRT-PCR using primers specific for 
each target gene and normalized to input chromatin subtracting IgG enrichment then 
normalized to the desert region. Data represent the average of four independent 
experiments ± S.E.M. measured in triplicate. Significance for differences relative to 
shGFP control was calculated using paired Student’s t-test (*, P < 0.05). D, ChIP qPCR 
analysis of H3K9me3 at a desert region on Chromosome 16. Cells were transduced and 
chromatin immunoprecipitated as in Panel C. Data represent the average of four 
independent experiments ± S.E.M. measured in triplicate.  
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also shown that anti-PDGF drugs significantly inhibited tumor growth and metastasis in 
tumors that express high levels of PDGFB (Hosaka et al. 2013). LCN2 can enhance the 
gelatinolytic activity of matrix metalloproteinase 9 (MMP9) on ECM (Yan et al. 2001). 
LCN2 has been shown to have pro-inflammatory functions and regulates cell growth 
and adhesion (Chakraborty et al. 2012). LOX is involved in extracellular matrix (ECM) 
remodeling by crosslinking collagen for matrix metalloproteinase 2 (MMP2) cleavage, 
thus promoting cell invasion and metastasis (Erler et al. 2006). LOXL2 may regulate 
extracellular and intracellular cell signaling pathways as well as function in ECM 
remodeling (Decitre et al. 1998). The association of KDM4B to these target gene 
promoters was increased 2-3 fold with exposure to hypoxia, consistent with the hypoxic 
induction of KDM4B protein (Figure 2.14B). With expression of shK-2, the most 
persistent and robust knockdown construct, KDM4B association was reduced to levels 
comparable to an isotype specific IgG control.  
Following knockdown of KDM4B there was increased enrichment of H3K9me3 at 
the promoters of these targets in 21% oxygen (Figure 2.14C). Although the overall level 
of H3K9me3 decreased abruptly in hypoxia (2% and 0.5% oxygen) compared to 21% 
oxygen, H3K9me3 levels at PDGFB and LCN2 promoter regions were significantly 
increased when knocking down KDM4B (Figure 2.14C). The H3K9me3 level at each 
target gene promoter was normalized to the enrichment of H3K9me3 on a control “gene 
desert” region, which was not affected by loss of KDM4B (Figure 2.14D). This suggests 
that chromatin accessibility was not systematically disrupted in hypoxia or altered by 
loss of KDM4B. These results demonstrate that KDM4B associates with regulatory 
regions of target genes, and demethylates the histones at promoters to maximize 
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hypoxic expression.  
Immunoblotting showed that knockdown of KDM4B with shK-2 decreased LCN2 
protein expression in both oxygen conditions, whereas the effect of shK-1 was only 
observed in normoxia (Figure 2.15). The glycosylated pre-pro-LOX peptide, which is 
made in the cell and then secreted to the extracellular milieu for further processing, was 
induced in hypoxia and decreased by KDM4B knockdown (Grimsby et al. 2010).  
Taken together, our results showed that KDM4B regulated metastatic gene by 
demethylating their promoters in ovarian cancer cells.  
 
DISCUSSION 
KDM4B regulates multiple aspects of cancer progression, including proliferation 
(Kawazu et al. 2011; Kim et al. 2012a), anti-apoptosis (Sun et al. 2014), DNA damage 
repair (Mallette et al. 2012; Zheng et al. 2013; Chen et al. 2014), and migration (Zhao et 
al. 2013e). In this chapter, we have demonstrated that KDM4B may contribute to cancer 
progression by regulating both general and tissue-specific target genes.  
Using microarray analyses, we have identified potential targets of KDM4B in 
cancer cell lines derived from three different cancer types, including SKOV3ip.1 ovarian 
cancer, HCT116 colon cancer, and RCC4 renal cell carcinoma. These three cancer 
types have shown dependence on hypoxic signaling during their development (Birner et 
al. 2001; Krishnamachary et al. 2003; Gudas et al. 2014). Mechanisms of how KDM4B 
may contribute to these cancers have not been clearly understood, especially in renal 
cell carcinoma (RCC) and epithelial ovarian cancer (EOC).  
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Figure 2.15. Expression of LCN2 and LOX protein in SKOV3ip.1 cells with KDM4B 
knockdown. SKOV3ip.1 cells were transduced with lentivirus expressing shRNA to 
KDM4B (shK-1 and shK-2) or control shRNA (shGFP). Cells were incubated in 21% or 
0.5% oxygen. LCN2 and LOX protein levels were determined by immunoblotting. 
Tubulin serves as a loading control. Images were chosen as representative of two 
independent experiments. Antibody dilution information is listed in Table 2.2. 
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Using microarray analyses, we have identified potential targets of KDM4B in 
cancer cell lines derived from three different cancer types, including SKOV3ip.1 ovarian 
cancer, HCT116 colon cancer, and RCC4 renal cell carcinoma. These three cancer 
types have shown dependence on hypoxic signaling during their development (Birner et 
al. 2001; Krishnamachary et al. 2003; Gudas et al. 2014). Mechanisms of how KDM4B 
may contribute to these cancers have not been clearly understood, especially in renal 
cell carcinoma (RCC) and epithelial ovarian cancer (EOC).  
By comparing KDM4B target genes in these three cell lines, we identified 16 
common targets that were regulated by KDM4B in all three cell lines. These genes 
display a variety of cellular functions, but are mostly related to cancer progression 
(Table 2.5 and Figures 2.3-2.6). For example, Claudin-12 (CLDN12) is a tight-junction 
protein that is overexpressed in colon, melanoma cancer cells, and multiple chemo-
resistant ovarian cancer cell lines and seemed to play important roles in tumorigenesis 
(Wang et al. 2006; Grone et al. 2007; Morita et al. 2008). Leucine zipper protein 6 
(LUZP6/MPD6) was identified as a tumor antigen in polycythemia vera, chronic 
myelogenous, and prostate cancer patients (Xiong et al. 2006). Monocyte to 
macrophage differentiation-associated (MMD) is involved in differentiation from 
monocyte to macrophage and is important for lung cancer cell proliferation (Li and He 
2014). Lysyl oxidase-related enzyme lysyl oxidase-like 2 (LOXL2) expression is 
correlated with metastasis and decreased survival in patients with aggressive breast 
cancer (Barker et al. 2011). Oncostatin M receptor (OSMR) was expressed by all 
human and canine osteosarcoma (OSA) cell lines and canine OSA tumor samples 
tested by Fossey et al (Fossey et al. 2011). OSM signaling promotes OSA cell invasion 
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and tumor angiogenesis by inducing STAT3 activation and enhancing the 
expression/activation of MMP2 and VEGF (Fossey et al. 2011). Paladin (PALLD) is 
overexpressed in many sporadic pancreas tumors and plays a role in the establishment 
of the TAF phenotype (Goicoechea et al. 2009). Human endoplasmic reticulum 
oxidoreductin 1-α (hERO1-α/ERO1L) is a hypoxia-inducible oxidizing enzyme that is 
overexpressed in cancer cells and is associated with poorer prognosis (Kutomi et al. 
2013). USP6 N-terminal-like protein (USP6NL/RN-tre), a GTPase-activating protein 
(GAP) for Rabs including Rab5 and Rab43, spatiotemporally controls focal adhesion 
remodeling during chemotactic cell migration (Palamidessi et al. 2013). ELAV 
(Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (ELAVL1/HuR) promotes 
cancer cell resistance to chemotherapy drugs or apoptosis by binding to the 3’-UTR of 
related gene mRNA (Licata et al. 2010; Lal et al. 2014; Winkler et al. 2014). Beta-site 
amyloid β precursor protein (APP)-cleaving enzyme 2 (BACE2) cleaves amyloid-β-
precursor protein, which may lead to aggregation of amyloid β and apoptosis (Farzan et 
al. 2000; Xie et al. 2007). DENND5A is a cancer driver candidate gene that is 
associated with intracellular trafficking and cell cycle progression (Li et al. 2014). ZAK, 
ZDHHC2 and DAZAP2 appear to have tumor suppressing potential (Yang 2002; Zhang 
et al. 2008; Lukas et al. 2009). Given the distinct phenotypes of CRC, RCC and EOC, 
studying the regulation of these genes may give us a better understanding of the 
general mechanisms of cancer progression, and may lead to the discovery of novel 
therapeutic methods targeting multiple cancer types.  
Although generally shared mechanisms exist, cancer is also a very heterogeneous 
disease. Each cancer has its own distinct genetic mutations and progression strategies. 
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For example, the canonical adenoma-carcinoma development of CRC is classified by 
Wnt pathway dysregulation (He et al. 1998). The most common genetic feature 
associated with clear cell RCC is loss or mutation of the von Hippel-Lindau (VHL) tumor 
suppressor gene, which results in stabilization of the HIFs, transactivating genes 
involved in angiogenesis, cell migration, and metabolism. EOC is the most 
heterogeneous cancer among the three. The majority of malignant EOC are 
characterized by mutations and/or loss of heterzygosity in TP53 and BRCA loci (Vang et 
al. 2009). Our current knowledge of KDM4B function in cancer points to mechanisms 
that are specific to each cancer type. For example, in breast cancer, KDM4B is 
regulated by the estrogen receptor and induces expression of pro-proliferative genes 
like Cyclin D1 (Yang et al. 2010). Androgens regulate KDM4B in prostate cancer, which 
in turn promotes PSA expression (Coffey et al. 2013). In colon and gastric cancers, 
KDM4B regulates β-catenin dependent gene expression and WNT signaling to promote 
attachment-free growth and metastatic behavior (Berry and Janknecht 2013; Zhao et al. 
2013a). In this study, we have also shown that the majority of KDM4B targets (≥75%) 
were involved in distinct pathways that were specific for each cancer type, indicating 
KDM4B may play distinct roles in different cancers (Figure 2.1 and Table 2.6-2.7). The 
hypoxic tumor microenvironment promotes tumor angiogenesis and metastasis, leading 
to a more malignant phenotype (Chan and Giaccia 2007; Semenza 2012). In our study, 
KDM4B showed differential targeting preference in different oxygen conditions, 
suggesting it may play different roles to support tumor survival in various steps of tumor 
progression. In normoxia, it preferentially regulated proliferative genes (cell cycle, 
cellular assembly, DNA replication/recombination/repair, and cell death), maintaining 
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cell functions to ensure fast growth of the tumor. In hypoxia, it switches to primarily 
regulating inflammatory and metastatic genes (cellular movement, cellular development, 
and cell-to-cell signaling), possibly promoting metastasis. This dual function of KDM4B 
in transcriptional regulation suggests that KDM4B may be an important factor in 
promoting cancer progression in different tumor microenvironments and may be a 
potential therapeutic target for cancer treatment.  
Because this differential regulation by KDM4B in different oxygen levels was 
most obvious in SKOV3ip.1 cells, we pursued mechanistic analysis in this cell line. Our 
microarray experiments suggest that KDM4B regulates the expression of multiple genes 
contributing to ovarian cancer growth and metastasis. In the case of most proliferative 
genes identified in the initial screen, this effect was attenuated with stable knockdown. 
KDM4D is the most likely compensatory enzyme, since we observed a robust increase 
in protein expression with the shK-1 construct in both cell lines (Figure 2.10). 
Compensatory Kdm4b expression has been observed in the testes of Kdm4d knockout 
mice, making it conceivable that our observations represent an inverse effect (Iwamori 
et al. 2011). Of greater interest is the regulation of genes with clear roles in promoting 
tumor progression and metastasis. PDGFB, LCN2, LOX and LOXL2 display 
dependence on KDM4B for maximum expression, with corresponding changes in 
histone methylation on their promoters. PDGFB is one of the secreted factors that 
promote angiogenesis and metastasis (Chantrain et al. 2006; Hosaka et al. 2013). 
LCN2 can enhance the gelatinolytic activity of matrix metalloproteinase 9 (MMP9) on 
ECM, thus promoting cell migration (Yan et al. 2001). LOX and LOXL2 both regulate 
cell migration through extracellular matrix (ECM) remodeling (Decitre et al. 1998; Erler 
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et al. 2006).  
EOC is typically diagnosed at a late-stage, where metastatic tumors have already 
disseminated throughout the peritoneal cavity and ascites fluid has developed (Lengyel 
2010). For this reason, mortality rate of EOC has not been improved over the past 30 
years (Lengyel 2010; Siegel et al. 2014d). After initial surgery and front-line treatment, 
EOC often recur with chemo-resistant tumors that reseed the peritoneal cavity within 2 
to 5 years. Therefore, a thorough understanding of the mechanisms underlying the 
metastatic behaviors of EOC is crucial for the development of more effective therapeutic 
methods. Inhibitors against PDGFB, such as sunitinib and sorafenib, have already been 
developed and used in clinical treatment for cancer, indicating KDM4B regulates 
important genes that can be targeted for improving cancer therapy (Widmer et al. 2014). 
Given the large cohort of potential KDM4B targets from the microarray analysis, our 
study has provided more opportunities to identify important target genes that may be 
useful for therapeutic treatment.  
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CHAPTER 3: 
THE HISTONE DEMETHYLASE KDM4B CONTRIBUTES TO PERITONEAL 
DISSEMINATION OF OVARIAN CANCER 
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ABSTRACT 
Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence due to 
widespread dissemination of peritoneal metastases at diagnosis. Multiple pathways 
contribute to the aggressive growth of EOC, including hypoxic signaling mechanisms. In 
this chapter, we have determined that the hypoxia-inducible histone demethylase 
KDM4B is expressed in high grade serous adenocarcinoma and EOC cell lines. KDM4B 
is expressed in approximately 60% of EOC tumors assayed, including primary, 
metastatic, and recurrent tumors. Suppressing KDM4B inhibits ovarian cancer cell 
invasion, migration and spheroid formation in vitro. KDM4B is also crucial for seeding 
and growth of peritoneal tumors in vivo, where its expression corresponds to hypoxic 
regions. Thus, KDM4B is a potent contributor to the seeding and growth of peritoneal 
tumors, one of the predominant factors affecting prognosis of EOC.  
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is the 10th most common cancer among women 
and the fifth leading cause of mortality, making it the most deadly of gynecologic 
cancers. The estimated mortality rate of EOC patients for the year 2015 is 67% (ACS 
2015). EOC is a highly heterogeneous disease, generally stratified by the 
aggressiveness of growth, with slower growing Type I tumors having better prognosis 
than more rapidly growing Type II tumors (Vang et al. 2009). The majority of Type II 
EOC patients are diagnosed at an advanced International Federation of Gynecology 
and Obstetrics (FIGO) stage (stage III or IV), with widespread dissemination of 
metastatic tumors throughout the peritoneal cavity (Naora and Montell 2005; Vang et al. 
2009; Lengyel 2010). Of the 4 general pathological subtypes that comprise EOC 
(serous, endometrioid, mucinous, and clear cell), the majority of the Type II (or high 
grade) EOC are high grade serous adenocarcinoma (HGSA), which represent 70% of 
the total EOC cases (Vang et al. 2009; Lengyel 2010).  
Recent genomic analyses have demonstrated that over 90% of HGSA patients 
have mutations in the tumor suppressor TP53, with significant proportions also 
containing mutations in BRCA1, BRCA2, and the pRB pathways (Cancer Genome Atlas 
Research 2011). The front-line therapy for HGSA consists of surgical debulking followed 
by treatment with platinating agents and taxol derivatives (Lengyel 2010). The initial 
response of patients to the combination of carboplatin and paclitaxel is generally 
effective, however resistant tumors typically recur within 2-4 years (Lengyel 2010). This 
rapid recurrence is caused by re-growth of residual, chemoresistant cancer cells 
residing in the peritoneal cavity. Moreover, this rapid re-establishment of tumor growth 
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suggests that a process inherent to epithelial ovarian cancer progression facilitates 
adaptation to the respective stresses imposed by the metastatic process, surgery, and 
chemotherapy.  
The hypoxic tumor microenvironment is a potent contributor to malignancy in 
multiple cancer types (Semenza 2012). The hypoxia-inducible factors (HIFs) are 
primary regulators of the hypoxic response, inducing multiple pathways utilized by 
tumors to promote homeostasis and tumor progression, including metabolic adaptation, 
self-renewal, angiogenesis, and metastasis (Semenza 2012). Consistent with the 
aggressively metastatic phenotype of EOC, elevated expression of HIF-1α hypoxia-
induced genes has been linked to poor patient outcome in ovarian cancer (Birner et al. 
2001; Chi et al. 2006). Further study of the hypoxic response in EOC may yield other 
clinically viable effector genes. 
Recent studies have determined that HIF-1α also regulates expression of 
Jumonji domain histone demethylases (JmjC-KDMs) and other epigenetic regulators 
(Beyer et al. 2008; Pollard et al. 2008; Wellmann et al. 2008; Krieg et al. 2010). The 
JmjC-KDMs are none-heme iron-dependent dioxygenases whose activities require 
oxygen, Fe (II) and 2-oxoglutarate (alpha-ketoglutarate) to demethylate histones and 
influence gene expression (Klose et al. 2007; Shi and Whetstine 2007; Yang et al. 2009; 
Mosammaparast and Shi 2010; Okada et al. 2010; Mimura et al. 2011). Among the 
approximately 30 different JmjC domain-containing histone demethylases (Pedersen 
and Helin 2010), KDM3A, KDM4B, KDM4C and KDM5B are directly regulated by HIF-
1α in response to hypoxia, establishing a compelling link between the hypoxic tumor 
microenvironment and epigenetic remodeling to support tumorigenesis  (Beyer et al. 
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2008; Pollard et al. 2008; Xia et al. 2009; Krieg et al. 2010).  
KDM4B expression is elevated in several cancer types and plays a significant 
role in tumor growth by driving cancer cell proliferation and inducing chromosomal 
instability (Yang et al. 2010; Slee et al. 2011; Kim et al. 2012a; Slee et al. 2012). 
KDM4B (Lysine-specific histone demethylase 4B, also called JMJD2B), catalyzes the 
demethylation of tri- and di-methylated histone H3 at Lysine 9 (H3K9me3/me2) and 
lysine 36 (H3K36me3/me2) (Whetstine et al. 2006). KDM4B regulates expression of cell 
cycle genes in breast cancer, including CCND1, CCNA1, WEE1, CDK6, MYB, and MYC 
(Yang et al. 2010; Kawazu et al. 2011). KDM4B also promotes epithelial-mesenchymal 
transition and metastasis in gastric cancer (Zhao et al. 2013a). Despite the significance 
of KDM4B in promoting proliferation and metastasis in several cancer types, its role in 
EOC progression has not been investigated. For this study, we hypothesized that if HIF-
1α and hypoxic signaling contribute to EOC (Chi et al. 2006), then KDM4B would also 
be expressed in EOC and influence its progression. Using a combination of 
immunohistochemical analysis of patient samples, in vitro functional analyses, and in 
vivo models of peritoneal ovarian cancer metastasis, we have determined that KDM4B 
is abundantly expressed in EOC tumors, and is a significant contributor to metastatic 
mechanisms in epithelial ovarian cancer cells, establishing a novel link between hypoxic 
induction of an epigenetic regulator and peritoneal tumor growth in epithelial ovarian 
cancers.  
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MATERIALS AND METHODS 
 
Cell Lines and Culture Conditions 
All OVCAR cell lines were maintained in RPMI-1640 (Invitrogen) supplemented 
with 10% heat-inactivated fetal bovine serum (HI-FBS) and 1% penicillin streptomycin 
(pen strep, Invitrogen). HIO80 cells were maintained in Medium 199 (Corning) mixed 
with MCDB 105 Medium (Sigma) at a 1:1 ratio, supplemented with 4% heat-inactivated 
fetal bovine serum (HI-FBS) and 1% pen strep (Invitrogen). SKOV3ip.1 cells were 
acquired from Dr. Erinn Rankin (Stanford University) with permission from Dr. Gordon 
Mills (M.D. Anderson Cancer Center). OVCAR3, OVCAR4, OVCAR5, OVCAR8, and 
IGROV1 cells were purchased from the NCI repository by Dr. Adam Krieg and Dr. 
Katherine Roby. OVCAR10 and HIO80 cells were from Dr. Andrew Godwin. Cells were 
transiently or stably knocked down of KDM4B depending on specific experimental 
needs as describe in Chapter 2. For overexpression of KDM4B, HIO80 cells were 
transduced with lentivirus containing either the wildtype KDM4B (WT, containing a silent 
mutation to escape recognition from shRNA) or the mutant KDM4B (mut, containing 
both the silent mutation and a catalytic mutation in its active site H189A). 
Overexpression of lacZ served as a control. For short-term hypoxia treatment (16-24 
hours), cells were incubated in Ruskinn InVivo300 glove-box hypoxic incubators (Baker) 
in which oxygen levels were maintained at 0.5% or 2% for 16-24 hours depending on 
specific experimental needs. For longer duration experiments (i.e. in vitro proliferation 
assays), cells were cultured in HeraCell150 incubators set to the indicated oxygen 
tension (Thermo Fisher Scientific, Inc.).  
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Antibodies  
Antibodies used in this chapter were: KDM4B (Cell Signaling; Cat# 8639, Clone 
D7E6), HIF-1α (BD; 610959), β-Actin (Sigma; A1978), PAX8 (Biocare; Cat# ACI 438A, 
Clone BC12), PDGFB (Santa Cruz; Cat# sc-127, Clone N-30), Ki67 (Thermo; RM-9106-
S0), and IgG control (Cell Signaling; Cat# 3900S, Clone DA1E). See Table 3.1 for 
specific dilutions in each assay of use. 
ImmunoBlotting. 
Cells were lysed in SDS lysis buffer (125 mM Tris-PH6.8, 1% SDS, 10 mg/ml 
Sodium Deoxycholate, 1 mM EDTA, 5 mM DTT) with protease inhibitor cocktail (Sigma-
Aldrich). Following SDS-PAGE, proteins were transferred to nitrocellulose and probed 
with the indicated primary and horseradish peroxidase conjugated secondary antibodies 
(See Table 3.1 for antibody dilution information). Chemiluminescent signal was detected 
with ECL Prime reagent (GE Healthcare) using a Bio-Rad Molecular Imager ChemiDoc 
XRS+ equipped with Image Lab Software (Bio-Rad). 
Tumor Microarray Samples  
Ovarian tissue microarrays (TMAs) were constructed by the KUCC Biospecimen 
Repository Core Facility. The TMAs were constructed using archival formalin fixed, 
paraffin embedded samples of primary ovarian carcinoma along with matched 
metastatic and recurrent tissue samples when available. These samples were identified 
from the pathology departmental archives of the University of Kansas Medical Center 
from 1998-2009. The TMA was composed of tumor tissue samples from 48 patients 
with ovarian cancer: 14 patients with primary, recurrence, and metastatic samples 
(including one patient with distant metastasis to the brain), 27 patients with primary and  
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Table 3.1. Antibody Dilutions. 
Assay Antigen Supplier Product NO. Discription Dilution 
Immuno
blot 
  
KDM4B Cell Signaling 8639 Rabbit mAb 1:1,000 
HIF1α BD 610959 Mouse mAb 1:1,000 
β-Actin Sigma A1978 Mouse mAb 1:2,000 
 α-Tubulin Thermo MS-581-PABX Mouse mAb 1:2,000 
 Rabbit IgG (H+L) KPL 474-1516 
Goat secondary 
Ab 1:5,000 
 Mouse IgG (γ) KPL 474-1802 
Goat secondary 
Ab 1:5,000 
IHC 
  
KDM4B Cell Signaling 8639 Rabbit mAb 1:100 
IgG control Cell Signaling 3900S Rabbit mAb 1:100 
PDGFB  Santa Cruz sc-127 Rabbit pAb 1:800 
PAX8 Biocare ACI438A Mouse mAb 1:100 
Ki67 Thermo RM-9106-S0 Rabbit mAb 1:800 
Pimonidazole Hypoxyprobe, Inc. 70132-50-2 Mouse mAb 1:5000 
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metastatic samples, and 7 patients with primary and recurrent samples. Based on 
review of the original pathology reports, the ovarian carcinomas were typed as serous 
(30 samples), mixed (14 samples; 12 of which included a serous component), 
carcinosarcoma (1 sample), clear cell (1 sample), papillary carcinoma, not otherwise 
specified (NOS) (1 sample) and adenocarcinoma, NOS (1 sample). For every sample, 
hematoxylin and eosin stained slides were reviewed by a board certified pathologist 
who selected tumor rich areas. Using the semi-automated TMArrayer (Pathology 
Devices, Inc., Westminster, MD) TMA paraffin blocks were assembled with triplicate 1.0 
mm cores using the marked slide as a guide. 
Immunohistochemical Analysis 
Immunohistochemical (IHC) staining was performed using standard 
peroxidase/DAB methods (See Table 3.1 for specific antibody dilution information). De-
paraffined sections subjected to antigen retrieval by incubating in 10mM Trisodium 
Citrate buffer, pH 6 at 95˚C for 10-30 minutes, depending on the antibody used. Tissue 
sections were counterstained with hematoxylin and then imaged on a Nikon 80i 
microscope with a Photometrics CoolSNAP ES camera and a NIS-Elements AR 
software to assess quality of staining. Isotype specific negative control antibodies were 
used for all comparisons. Human TMA slides were scanned using an Aperio slide 
scanning microscope (Leica) at both University of Kansas Medical Center Department 
of Pathology and the University of California San Francisco Department of Radiation 
Oncology. Individual spot images were extracted using Aperio TMALab. Stained slides 
were independently reviewed and evaluated by at least 2 board certified pathologists 
(authors TK, GT, OT) without prior knowledge of the clinical diagnosis or outcome. For 
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KDM4B, tumors were scored based on extent of nuclear staining, with extent defined as 
the percentage of epithelial tumor cells staining positive for KDM4B (negative, 0%-10% 
of cells expressing; positive, >10% of cells expressing). For CA-IX and PDGFB, tumors 
were scored on a qualitative scale that integrated both intensity and extent of staining (0 
= no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining). Scores for 
the triplicate spots from each tumor biopsiy were averaged for statistical analysis. SPSS 
statistical software (IBM) was used to determine significance of coexpression with 
KDM4B using Bivariate correlation and Mann-Whitney U-test. 
QRT-PCR. 
Quantitative real-time PCR (qRT-PCR) was conducted as described in Chapter 
2. All primers used for RNA analysis used in this chapter are listed in Table 3.2.  
Cell Proliferation Assay. 
For the short-term assay, approximately 50,000 SKOV3ip.1 cells transiently 
transfected with either siK4B or siCon were plated in each 6-cm cell culture dish and 
allowed eight hours to attach to the dish. After the eight-hour incubation at 21% oxygen, 
one dish of cells from each line (siK4B or siCon) were trypsinized, stained with Trypan 
blue and counted (as Day 0). Hypoxic treatment began after the Day 0 count and one 
dish of cells from each group were counted every 24 hours for four days. A long-term 
proliferation assay was conducted as described previously (Welford et al. 2006), with 
minor modifications. Briefly, SKOV3ip.1 cells were stably transduced with lentivirus 
containing shGFP, shK-1 or shK-2 as described in the Cell culture condition section. 
Approximately 50,000 cells were plated per 6-cm dish. Cells were counted using a 
hemocytometer every three days and 50,000 cells were plated back into the dish after  
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Table 3.2. QPCR Primers Used in This Chapter. 
Gene Forward (5'-3') Reverse (5'-3') 
hsKDM4B ggactgacggcaacctctac cgtcctcaaactccacctg 
hsKDM4A gccgctagaagtttcagtgag gcgtcccttggacttcttatt 
hsKDM4C aggcgccaagtgatgaag gagaggtttcgcccaagact 
hsKDM4D ggacaagcctgtaccactgag ctgcacccagaagccttg 
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counting each time. Cells were counted in triplicate using five fields per sample. Four 
independent experiments were recorded and total cell numbers were calculated based 
on the number of cells from each count and the dilution factor from each passage.  
For overexpression experiments, HIO80 cells were stably transduced with 
lentivirus containing the lacZ, WT or mut KDM4B as described in the Cell culture 
condition section. Cells were plated and counted the same way as in the SKOV3ip.1 
3T3 proliferation assay. 
Boyden Chamber Migration and Matrigel Invasion Assay. 
For invasion assays, Boyden chambers (BD Falcon, 8 micron pore size) were 
coated with 100 uL Matrigel (BD Biosciences, diluted to 1 mg/ml in serum free RPMI). 
Uncoated Boyden chambers were used for migration assays. Fifty thousand cells were 
distributed to chambers and incubated for 24 hours in 21%, 2% or 0.5% oxygen. Cells 
that invaded and/or migrated through the membrane were released by trypsinization 
and quantified using CyQUANT Cell Proliferation Assay Kit (Life Technologies) 
according to manufacturer’s protocol, with modifications developed by Swenson-Fields 
et al. (Swenson-Fields et al. 2013). DNA content in each group was calculated and the 
significance of the difference between control and experimental groups were 
determined using two-tail paired Student’s t-test. Cells seeded as monolayers served as 
controls for any potential proliferation or viability defects resulting from KDM4B 
knockdown.  Aliquots of 50,000 frozen cells also served as internal controls for plating 
density. Representative membranes were also fixed and stained with Siemens Diff Quik 
Stain Set (Neobits, Inc.) and imaged using a Leitz LABORLUX12 microscope. Images 
were captured using LAS EZ software and a Leica EC3 camera. 
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Soft Agar Assay.  
Soft agar assay was conducted according to the established protocol from 
Gjoerup Lab (Zhao et al. 2003; Cheng et al. 2009), with minor modifications. Briefly, 
0.6% agar was coated on the bottom of each well of a six-well tissue culture dish. 
Approximately 2,500 cells were mixed in growth media containing 0.3% agar and were 
cultured on top. Two milliliters of growth media was added and replaced every other day 
to keep sufficient nutrient and moisture. For hypoxic treatment, cells were incubated in a 
HeraCell150 incubator (Thermo Fisher Scientific, Inc.) set at 2% oxygen. After four to 
six weeks of incubation, colonies were stained with 0.005% crystal violet. Five 
representative fields (top, bottom, left, right, and middle) were imaged with a Q-
IMAGING camera installed on a Leica MZFLIII dissecting microscope for each well. 
Spheroid Formation Assay. 
Approximately 600 cells were seeded per well of 96-well ultra-low attachment 
plates (Corning Incorporated). After four days, spheroids were imaged by brightfield 
microscopy using a Leica DMI 4000 inverted microscope equipped with a Leica CCD 
camera (Courtesy of Dr. Michael J. Soares, KUMC). Volume (𝑉 = 4
3
𝜋𝑟3) was calculated 
after measuring the diameter and radius of each spheroid using NIH Image J (Vinci et 
al. 2012). Differences in average spheroid volume were analyzed by two-tail paired 
Student’s t-test. 
Intraperitoneal Tumor Xenografts. 
SKOV3ip.1 and OVCAR8 cells were transduced with lentivirus to express firefly 
luciferase (pLenti PGK V5-LUC Neo (w623-2), a gift from Eric Campeau (Addgene 
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plasmid # 21471) (Campeau et al. 2009)). Following neomycin selection, KDM4B was 
knocked down using pLKO.1-puro constructs as described the Cell culture condition 
section. One million SKOV3ip.1-luc-neo cells or five million OVCAR8-luc-neo cells (in 
200 µl of sterile serum-free RPMI 1640) were injected into the peritoneal cavity of nude 
mice (Taconic; 4-6 weeks old). Ten mice were injected per group. Each week following 
injection, each mouse (approximately 20-25 g in weight on average) was injected with 
200-250 μl D-Luciferin (15 mg/mL in sterile PBS, Gold Biotechnology, Inc.) and 
bioluminescence measured with an IVIS Spectrum in vivo imaging system (Perkin 
Elmer) in the KUMC Center for Molecular Imaging. All mice were euthanized at humane 
end points for the shGFP control mice (approximately 4.5 weeks and 6.5 weeks post 
injection for SKOV3ip.1 and OVCAR8 cells, respectively). 30 minutes before 
euthanasia, animals were injected i.p. with pimonidazole (Hypoxyprobe, HPI) to label 
hypoxic cells. Significance of KDM4B-dependent changes in bioluminescent signal, 
tumor mass, and ascites volume were determined using Mann-Whitney U test 
compared to control (shGFP) mice. 
All tumors were dissected, weighed, and flash-frozen or fixed for later analysis. If 
present, ascites fluid from each mouse was collected and the volume recorded. Frozen 
tumor samples were homogenized and processed to purify protein and RNA for gene 
expression analysis by qRT-PCR. Portions of the largest tumors (primarily omental 
masses) were fixed in 4% Paraformaldehyde in PBS, paraffin-embedded, and sectioned 
for IHC using antibodies against KDM4B, PAX8, Ki67, and pimonidazole. 
Representative slide images were captured using a Nikon 80i equipped with a 
Photometrics CoolSNAP ES camera running NIS-Elements AR image acquisition 
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software. 
 
RESULTS 
KDM4B is Abundantly Expressed in High Grade Ovarian Serous Adenocarcinoma 
Tumors and OVCAR Cell Lines 
Hypoxic signaling mechanisms contribute to the progression of multiple cancer 
types, including epithelial ovarian cancers (Chi et al. 2006). Since hypoxic regulation of 
KDM4B is a common mechanism in many different cancer cell types (Beyer et al. 2008; 
Wellmann et al. 2008; Xia et al. 2009; Krieg et al. 2010), we hypothesized that KDM4B 
would also be robustly expressed in EOC, and contribute to tumor growth. In order to 
test our hypothesis, we obtained ovarian cancer tissue microarrays from the University 
of Kansas Cancer Center and measured KDM4B expression using 
immunohistochemistry (See Material and Methods and Table 3.3). These arrays contain 
representative biopsies from 48 primary EOC tumors with matched metastatic (42) and 
recurrent ovarian cancer sections (22, as available). Approximately 60% of the total 
tumor biopsies were collected from high grade serous adenocarcinoma patients (30 
primary, 29 matched metastases, with 10 matched recurrent tumors). The remaining 18 
tumors displayed combinations of serous, clear cell, endometrioid, and mucinous 
features (See Materials and Methods and Table 3.3 for a more complete description). 
KDM4B nuclear staining was significantly over-expressed compared to the normal 
ovarian sections, with more than 60% of the tumors staining positive for KDM4B (i.e. 
more than 10% of the tumor epithelium had detectable nuclear staining), while none of 
the tissues from normal ovarian punches stained positive  (Fig. 3.1A-D). KDM4B was  
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Table 3.3. Analysis of KDM4B expression in normal ovary, and primary EOC 
tumors with matched metastatic and recurrent tumors. 
Samples 
  
Number of samples with High 
or Low KDM4B expression (% 
of samples)   % nuclei positive for KDM4B 
  High  Low  Total   Mean Median STDEV Range 
Normal 
Ovary 
  0 9 (100) 9   0.4 0.3 0.4 0-1 
                  
High 
Grade 
Serous 
Primary 19 (63.3) 11 (36.7) 30   22.4 20.8 18.6 0.7-61.1 
Metastases 20 (69) 9 (31) 29   19.0 17.6 13.6 0-54.2 
Recurrence 6 (60) 4 (40) 10   14.5 11.2 17.8 0.2-60.2 
Totals 45 (65) 24 (35) 69   19.8 16.0 16.5 0-61.1 
                  
Mixed  
Primary 9 (64.3) 5 (35.7) 14   17.5 14.4 15.9 0.4-44.5 
Metastases 3 (37.5) 5 (62.5) 8   10.4 5.1 10.9 1.3-30.2 
Recurrence 6 (54.5) 5 (45.5) 11   10.3 10.8 10.6 0.3-38.5 
Totals 18 15 33   13.4 11.1 13.3 0.3-44.5 
                  
Other 
Primary 4 (100) 0 4   18.6 18.5 6.9 10.4-27.1 
Metastases 2 (50) 2 (50) 4   19.9 18.5 19.3 1.8-40.7 
Recurrence 0 0 0   NA NA NA NA 
Totals 6 (75) 2 (25) 7   19.3 18.5 13.4 1.8-40.7 
                  
Numbers of samples with High or Low KDM4B expression are represented as n (%). Tumors with > 10% 
nuclei staining positive for KDM4B were considered "high," in a modification of a method described in 
(Goode, et al. 2011, See materials and Methods). “Mixed” contain various combinations of clear cell, 
endometrioid, and mucinous characteristics, all with a serous component. Other contains individual tumors 
with diagnosis of endometrioid, clear cell, or carcinosarcoma. 
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Figure 3.1. KDM4B is robustly expressed in ovarian cancer tissue and ovarian 
cancer cell lines compared to normal ovarian surface epithelial cells. A, 
Representative immunohistochemical detection of KDM4B (top row; brown, DAB; blue, 
hematoxylin) in Tumor Microarray sections from normal ovary and high-grade ovarian 
serous adenocarcinoma biopsies with matched primary, metastatic and recurrent tumor 
sections. IgG (middle) and H&E (hematoxylin and eosin, bottom) serve as controls for 
non-specific DAB staining and tissue structure controls, respectively. B, Representative 
IHC images of tumor sections with high (left) and low (right) KDM4B. For A and B, scale 
bar for entire section, 100 μm; scale bar for inset, 50 μm. C, Box-whisker plot of KDM4B 
nuclear staining in normal ovary (9), primary HGSA tumors (30), metastases (29), and 
recurrent tumors (10). Diamond, mean; solid bar, median; top and bottom boxes, 75 and 
25 percentile; top and bottom whiskers, high and low. D, Percentage of total patient 
samples in each category (normal, primary, metastasis and recurrence) staining for high 
or low KDM4B (high > 10% nuclei staining positive for KDM4B). F, KDM4B expression 
in representative normal ovarian surface epithelium. Scale bar, 100 μm. 
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robustly expressed in multiple ovarian cancer cell lines representing a broad range of 
EOC genotypes, particularly in response to hypoxia (0.5% oxygen) (Fig. 3.2). In an 
independent validation using sections derived from normal ovaries from reproductive 
age women, there was weak KDM4B staining in normal ovarian surface epithelium 
(OSE, Fig. 3.1E), one potential source tissue for EOC (Lengyel 2010). Additionally, 
there was weak hypoxic induction of KDM4B in the immortalized OSE cell line HIO80 
(Fig. 3.2). Taken together, we conclude that KDM4B is over-expressed in epithelial 
ovarian cancer cells may be an important factor contributing to progression of HGSA.   
KDM4B Regulates In Vitro Cell Invasion, Migration, and Anchorage-Independent 
Growth in Normoxia and Hypoxia 
Expression microarray analysis indicated that suppression of KDM4B with 
transiently transfected siRNA disrupted the regulation of multiple genes with well-
described roles in cell proliferation, particularly in normoxic conditions. To determine if 
regulation of proliferative genes in EOC cells was a significant effect, SKOV3ip.1 cells 
were transiently transfected with siRNA to KDM4B, and the cells seeded for short-term 
proliferation assays in 21%, 2%, and 0.5% oxygen (See Materials and Methods, 
knockdown efficiency was demonstrated in Figure 2.1A and 2.8). By the third day, cell 
proliferation was significantly reduced in 21% oxygen following KDM4B knockdown 
compared to the non-silencing control, but not in either 2% oxygen or 0.5% oxygen (Fig. 
3.3A-C). These results are consistent with the general decrease in expression of 
proliferative genes in normoxia described in Figure 2.9A, with little effect of KDM4B in 
hypoxia. In subsequent experiments using stably integrated shRNA constructs in a long-
term proliferation assay, SKOV3ip.1 cells displayed little biologically significant  
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Figure 3.2. KDM4B protein expression in ovarian cancer cell lines. Immunoblot 
detection of KDM4B and HIF-1α in a panel of ovarian cancer cell lines in normoxia (N, 
21% oxygen) and in hypoxia (H, 0.5% oxygen). HIO-80 cells serve as non-transformed 
OSE control. Beta-actin serves as loading control for the KDM4B blot. 
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Figure 3.3. Regulation of SKOV3ip.1 cell proliferation by KDM4B. A-C, SKOV3ip.1 
cells were transfected with siRNA to KDM4B (grey line) or an irrelevant control (black 
line), seeded for short-term proliferation experiments (See Materials and Methods), and 
cultured in 21% O2 (A), 2% O2 (B), 0.5% O2 (C). Data represent four independent 
experiments. *, P<0.05, determined by nonlinear regression. DT, doubling time (days), 
siCon vs siK4B. D-E, Long-term cell proliferation assay. SKOV3ip.1 cells transduced 
with shRNA to KDMB (shK-1 and shK-2) were seeded for long-term cell proliferation 
assays as described in Materials and Methods, and cultured in 21% O2 (D) and 2% O2 
(E). Data represent four independent experiments. Significance was determined using 
nonlinear regression (#, P<0.05, comparing shK-1 to shGFP; *, P<0.05, comparing shK-
2 to shGFP). DT, doubling time (days), shGFP vs shK-1 vs shK-2. F-G, Long-term cell 
proliferation assay. HIO80 cells transduced with lentivirus containing wildtype (WT) or 
H189A mutated (mut) KDM4B were seeded for long-term cell proliferation assays as 
described in Materials and Methods, and cultured in 21% O2 (F) and 2% O2 (G). Data 
represent three independent experiments. Significance was determined using two-tailed 
paired Student’s t-test. DT, doubling time (days), lacZ vs WT vs mut. H, Immunoblotting 
showing overexpression of WT and mut KDM4B in HIO80 cells in normoxia (21% O2) 
and hypoxia (1% O2). KDM4B expression in RCC4 cells served as a positive control. 
Tubulin served as a loading control for the same blot.  
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dependence on KDM4B for cell growth in any oxygen condition tested (0.1-0.2 day 
increase in doubling time), although the difference was still statistically significant 
(Figure 3.3D-E, knockdown efficiency was demonstrated in Figure 2.10), possibly due to 
compensation from one of the other KDM4 histone demethylases (Figure 2.11). 
Combined, these results indicate that the regulation of proliferative genes by KDM4B is 
not the most significant contributing factor to ovarian cancer progression. A separate 
experiment with the non-transformed cell line HIO80 showed that overexpression of 
KDM4B did not increase cell proliferation (Figure 3.3F-G, KDM4B expression level 
validated in Figure 3.3H). 
Expression analysis also indicated that KDM4B regulated several metastatic 
genes and pathways (i.e. PDGFB, LOXL2, LOX, and LCN2; Figure 2.9C, 2.13-14). In 
the case of EOC, metastasis typically occurs as peritoneal dissemination, where the 
primary tumors shed cancer cells into the peritoneal cavity. Free-floating cells in the 
peritoneum establish tumors throughout the omentum, visceral fascia, and mesothelial 
lining of the abdominal cavity (Naora and Montell 2005; Lengyel 2010). This unique 
mechanism of metastasis restricts most of the relevant mechanisms to invasion, 
migration, and attachment-free growth. SKOV3ip.1 and OVCAR8 cells expressing shK-
1 and shK-2 were seeded to Boyden chamber migration and invasion assays (Figure 
3.4 and 3.5). Consistent with the observed alterations in metastatic genes from the 
microarray expression analysis, both SKOV3ip.1 and OVCAR8 cells demonstrated a 
dependence on KDM4B for invasion through Matrigel, with at least 60% decrease in 
invasive capacity for shK-2 in all conditions tested (Figure 3.4A and 3.5A). In 
SKOV3ip.1 cells, shK-1 is a less effective construct under hypoxia (Figure 3.4A-B), so  
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Figure 3.4. KDM4B supports SKOV3ip.1 cell invasion and migration. A, SKOV3ip.1 
Matrigel Invasion Assay. SKOV3ip.1 cells expressing shRNA to KDM4B (shK-1 and 
shK-2) were seeded to Boyden Chambers coated with Matrigel and processed as 
described in Methods. Data represent mean ± S.E.M for five independent experiments 
conducted in triplicate. B, Migration Assay. SKOV3ip.1 cells were seeded to empty 
Boyden chambers, cultured and quantified as in Panel A. Data represent mean ± S.E.M 
for five independent experiments conducted in triplicate. C, SKOV3ip.1 proliferation 
control for Boyden Chamber Migration and Matrigel Invasion Assay. SKOV3ip.1 cells 
were grown as monolayers for 24 hours, trypsinized, frozen, and analyzed in parallel 
with the cells in the migration and invasion groups (A-B). Data represent mean ± S.E.M. 
Results were averaged from five independent experiments conducted in triplicate. For 
Panels A-C, significance was calculated relative to shGFP control at each oxygen 
condition, using Mann Whitney U-tests (*, P<0.05; #, P<0.005). D, Representative 
image of SKOV3ip.1 invasion assay. Filters treated in parallel to those in Panel A were 
fixed and stained, as described in Materials and Methods. 100X magnification, scale bar 
= 200 μm.  
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Figure 3.5. KDM4B supports OVCAR8 cell invasion and migration. A, OVCAR8 
Matrigel Invasion Assay. OVCAR8 cells expressing shRNA to KDM4B (shK-1 and shK-2) 
were seeded to Boyden Chambers coated with Matrigel and processed as described in 
Methods. Data represent mean ± S.E.M for four independent experiments conducted in 
triplicate. B, Migration Assay. OVCAR8 cells were seeded to empty Boyden chambers, 
cultured and quantified as in Panel A. Data represent mean ± S.E.M for four 
independent experiments conducted in triplicate. C, OVCAR8 proliferation control for 
Boyden Chamber Migration and Matrigel Invasion Assay. OVCAR8 cells were grown as 
monolayers for 24 hours, trypsinized, frozen, and analyzed in parallel with the cells in 
the migration and invasion groups (A-B). Data represent mean ± S.E.M. Results were 
averaged from four independent experiments conducted in triplicate. For Panels A-C, 
significance was calculated relative to shGFP control at each oxygen condition, using 
Mann Whitney U-tests (*, P<0.05). D, Representative image of OVCAR8 invasion assay. 
Filters treated in parallel to those in Panel A were fixed and stained, as described in 
Materials and Methods. 100X magnification, scale bar = 200 μm.  
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while there was a trend of reduced invasion and migration, attenuation of migration was 
only significant in 2% oxygen. In OVCAR8 cells, invasion through Matrigel and migration 
through the empty inserts were severely attenuated with both shRNA constructs (>80%) 
(Figure 3.5A-B), indicating that while KDM4B was universally important for regulating 
invasive behavior in either cell line, its effects may be mediated through distinct, but 
overlapping mechanisms. This effect was not due to defect of cell proliferation, as 
tested in a paralleled proliferative control experiment (Figure 3.4C and 3.5C). 
Another characteristic of metastatic EOC cells is the ability to grow as clusters of 
cells suspended in peritoneal ascites (Lengyel 2010). When SKOV3ip.1 cells were 
embedded in soft agar, cells transfected with siK4B grew smaller and fewer colonies 
compared to siCon cells (Figure 3.6A). Using a quantitative assay to measure the 
formation of single spheroids in ultra-low attachment plates, we determined that loss of 
KDM4B significantly reduced the size of spheroids by a factor of at least 50% in 
SKOV3ip.1 cells, with similar results in OVCAR8 cells (Figure 3.6B-C). Additionally, the 
shapes of the spheroids displayed with the appearance of frayed boundaries in the 
knockdown groups compared to the shGFP controls (Figure 3.6D-E). Combined, these 
results indicate that KDM4B may influence ovarian cancer progression by promoting 
formation of ascites spheroids in the peritoneal cavity and subsequent invasion of these 
clusters to peritoneal tissues. 
KDM4B is Required for Peritoneal Tumor Growth  
To determine if loss of KDM4B influenced tumor progression in vivo, SKOV3ip.1 
and OVCAR8 cells were stably transduced with firefly luciferase (See Materials and 
Methods). KDM4B was knocked down with shRNA, and cells were injected i.p. into  
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Figure 3.6. KDM4B supports ovarian cancer cell attachment-free growth. A, 
SKOV3ip.1 soft agar spheroid formation assay. SKOV3ip.1 cells transfected with 
shRNA to KDM4B were cultured in 0.3% soft agar in tissue culture dish coated with 0.6% 
soft agar. Cells were incubated in 21% and 2% O2 as described in Materials and 
Methods. Images were taken after 2 weeks of incubation. 10X magnification, scale bar = 
1 mm. B, SKOV3ip.1 spheroid formation assay. SKOV3ip.1 cells transduced with 
shRNA to KDM4B were cultured in 3D spheroid formation assays in 21% and 2% O2 as 
described in Materials and Methods. After four days, spheroid volume was calculated. 
Data represent mean volume ± S.E.M. 16 spheroids for each shRNA construct. C, 
Representative images (median volume) of SKOV3ip.1 spheroids. 100X magnification, 
scale bar = 100 μm. D, OVCAR8 spheroid formation assay, conducted as described for 
B. E, Representative images (median volume) of OVCAR8 spheroids. 100X 
magnification, scale bar = 100 μm. For Panels B and D, significance was calculated 
relative to shGFP control at each oxygen condition, using Mann Whitney U-tests (*, 
P<0.05; #, P<0.005).  
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nude mice. Tumor seeding and growth was monitored weekly by bioluminescence. At 
experimental endpoint, KDM4B knockdown significantly decreased tumor signal in mice 
(Figure 3.7 and 3.8). Quantitation of the total photon flux revealed a significant decrease 
in accumulation of tumor burden in cells expressing shRNA to KDM4B (Figure 3.9). This 
effect was significant for both shK-1 and shK-2 in SKOV3ip.1 cells, whereas shK-2 
showed a more significant effect in slowing OVCAR8 tumor growth than shK-1 (Figure 
3.9). Total endpoint tumor weight was significantly decreased by at least 50% with both 
shRNA constructs in SKOV3ip.1 cells and with shK-2 in OVCAR8 cells (Figure 3.10A-
B). OVCAR8 cells expressing the shK-2 construct developed significantly less ascites 
fluid compared to the shGFP control, while shK-1 showed an intermediate decrease in 
total ascites volume (Figure 3.10C). Terminal necropsy confirmed a general decrease in 
the size of metastatic nodules in the omentum, viscera, and peritoneal wall. (See 
representative images, Figure 3.11). Combined, these studies demonstrate a 
requirement for KDM4B in the establishment and growth of peritoneal tumors.  
KDM4B is Expressed in Hypoxic Regions of Tumors  
Immunohistochemical detection of KMD4B in xenograft tumors confirmed the 
stability of knockdown throughout the study (Figure 3.12A-D), while also demonstrating 
coexpression of KDM4B with tumor hypoxia (Figure 3.12E-L, as measured by 
pimonidazole and PAX8 staining to detect hypoxia and EOC tumor epithelium, 
respectively). There was no apparent difference in cell proliferation (Ki-67 staining, 
Figure 3.12M-P), supporting the in vitro observations that stable knockdown of KDM4B 
had little effect on cell proliferation in monolayers (Figure 3.3). QPCR measurement of 
KDM4B, KDM4A, KDM4C, and KDM4D RNA in both SKOV3ip.1 and OVCAR8 derived  
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Figure 3.7. KDM4B regulates in vivo peritoneal growth of SKOV3ip.1 cells. Ventral 
bioluminescent images of nude mice injected with SKOV3ip.1-luc-neo cells transduced 
with KDM4B shRNA contructs, compared to shGFP control. Images were taken weekly 
after injection.  
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Figure 3.8. KDM4B regulates in vivo peritoneal growth of OVCAR8 cells. Ventral 
images of mice injected with OVCAR8 cells transduced with the indicated KDM4B 
shRNA contructs. Images were captured weekly after injection.   
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Figure 3.9. KDM4B regulates in vivo peritoneal growth of ovarian cancer cells. A, 
Longitudinal measurement of ventral bioluminescence for all mice injected with 
SKOV3ip.1-luc-neo transduced with shGFP control (blue line, n=10), shK-1 (green line, 
n=10), and shK-2 (red line, n=9). Data represents mean total radiance (photons/sec) for 
each group ± SEM. B, Longitudinal dorsal bioluminescence for SKOV3ip.1 study, 
analyzed as in A. C, Longitudinal measurement of ventral bioluminescence for all mice 
injected with OVCAR8-luc-neo transduced with shGFP control (blue, n=10), shK-1 (red, 
n=10), and shK-2 (green, n=10). Data represents mean total radiance (photons/sec) for 
each group ± SEM. D, Longitudinal dorsal bioluminescence for OVCAR8 study, 
analyzed as in C. Statistics were calculated by Kruskal Wallis and Mann Whitney U-
tests (*, P<0.05; **, P<0.005). Blue asterisks, difference among all three groups; red 
asterisks, difference between shK-1 and shGFP; green asterisks, difference between 
shK-2 and shGFP.  
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Figure 3.10. KDM4B regulates in vivo peritoneal growth and ascites formation of 
ovarian cancer cells. A, Mean total tumor weight ± S.E.M. for SKOV3ip.1 xenografts. n 
≥ 9. (*, P<0.05; #, P<0.005, Mann-Whitney U-test). B, Mean total tumor weight ± S.E.M. 
for OVCAR8 xenografts. n ≥ 9. (*, P<0.05; #, P<0.005, Mann-Whitney U-test). C, 
Ascites collected from OVCAR8 experiment. Box-Whisker plot of ascites fluid volume. 
Short bold bar, mean; solid bar, median; n ≥ 9. (*, P<0.05, determined by Mann-Whitney 
U-test).  
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Figure 3.11. KDM4B regulates in vivo peritoneal growth and dissemination of 
ovarian cancer cells. Representative images of end-point necropsy showing tumor 
distribution in mice injected with SKOV3ip.1 or OVCAR8 cells carrying shRNA to GFP 
control or KDM4B, as indicated. Scale bar = 1 cm. Visible tumors are circled in yellow. 
Note the large cluster of fused omental tumors in the shGFP controls, compared to the 
knockdown mice.  
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Figure 3.12. KDM4B is expressed in hypoxic regions of tumor xenografts. A-D, 
KDM4B. E-H, Pimonidazole. I-L, PAX8. M-P, Ki67. Q-T, IgG. U-X, H&E. Scale bar, 100 
μm. N, necrosis; H, hypoxia.  Panels A, E, I, M, Q, and U correspond to SKOV3ip.1 
shGFP control tumor sections. Panels B, F, J, N, R, and V correspond to SKOV3ip.1 
shK-2 KDM4B knockdown tumor sections. Panels C, G, K, O, S, and W correspond to 
OVCAR8 shGFP control tumors. Panels D, H, L, P, T, and X correspond to OVCAR8 
shK-2 tumor sections. All IHC sections were counterstained with hematoxalin to 
visualize cell nuclei. Images were captured at 100X magnification. Scale bar = 200 μm.  
  
 135 
  
 136 
Figure 3.13. Post-mortem KDM4 Family Member Expression. A, QRT-PCR 
measurement of KDM4 subfamily members in SKOV3ip.1 xenograft tumors, as 
described in Methods. (shGFP, n=9; shK-1, n=9; shK-2, n=8). B, QRT-PCR 
measurement of KDM4 subfamily members in OVCAR8 xenograft tumors.  (shGFP, 
n=10; shK-1, n=9; shK-2, n=8). Data represents average fold change relative to shGFP 
control, after normalization to homo sapiens GAPDH. Significance calculated by Mann 
Whitney U-test relative to shGFP control (*, P < 0.05).  
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tumors (Figure 3.13) provided additional confirmation of stable knockdown of KDM4B, 
while also identifying slight increases in expression of KDM4D. 
To further confirm that KDM4B expression in EOC was associated with tumor hypoxia, 
the expression of Carbonic anhydrase 9 (CA-IX), a potent marker of tumor hypoxia was 
also scored in the KUCC OVCAR TMAs (Figure 3.14A for representative comparison, 
and Figure 3.14B for a scatter plot of the IHC scoring, raw score summaries are listed in 
Table 3.4). Average intensity of CA-IX staining for triplicate tumor sections in the serous 
tumors (range 0-3) was positively correlated to the percentage of KDM4B-positive tumor 
nuclei (Pearson’s correlation r = 0.390, P = 0.001, for all tumors combined). When the 
primary and metastatic tumors were analyzed separately, this correlation extended 
individually to both groups (r = 0.357 and 0.472, respectively), although significance was 
achieved only in the metastatic group (P=0.03). When samples were divided into “High” 
and “Low” CA-IX groups (High >2 average score), KDM4B scores were significantly 
higher in the samples expressing more CA-IX (Figure 3.14C, p=0.026, Mann-Whitney 
U-test for primary and metastatic tumors combined). Similarly, the association between 
KDM4B and the putative target gene PDGFB was also apparent in the TMA data 
(Figure 3.14A, D-E). PDGFB was positively correlated with KDM4B expression in all 
serous tumors (r=0.245, P=0.044), with similar correlations in the individual primary and 
metastatic groups (r= 0.318 and 0.382, respectively), although the correlation was only 
significant in the metastatic tumors (P=0.043). When samples were separated by the 
median KDM4B score for combined primary and metastatic tumors, the segregation of 
PDGFB scores was also significant (P=0.01, Figure 3.14E). Considering the relatively  
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Figure 3.14. KDM4B is preferentially expressed in hypoxic ovarian cancer tumors 
to promote progression. A, Representative images of high and low KDM4B staining 
TMA sections with matched CAIX and PDGFB staining. IgG and H&E serve as negative 
and tissue structure controls, respectively. Scale bar = 50 μm. B, Scatter plot of hypoxia 
(CA9 staining) vs KDM4B staining in TMA sections. Blue diamonds, primary tumors; red 
squares, metastatic tumors; green triangles, recurrent tumors. C. Box-Whisker Plot of 
KDM4B staining in High vs Low CA-IX. Data represent combined primary and 
metastatic tumors. Statistics were calculated by Mann Whitney test. *, P<0.05. D, 
Scatter Plot of PDGFB vs. KDM4B staining in TMA sections.  E, Box-whisker plot of 
correlation between KDM4B and PDGFB staining in TMA sections. Samples were 
segregated by median KDM4B score for primary and metastatic samples combined. 
Statistics were calculated by Mann Whitney test, relative to shGFP control. *, P<0.05.  
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Table 3.4. Immunohistochemical Scoring Data for KUCC OVCAR TMAs. 
Patient Grade histosubtype tumor type 
 KDM4B 
(Avg. % 
nuclear 
staining) 
PDGFB (Avg 
Intensity 
score) 
CA9 (Avg 
Intensity 
Score) 
1 III serous primary 35.47 2.00 3.00 
2 III serous primary 2.90 2.00 2.00 
3 III serous primary 21.93 0.33 3.00 
4 III serous primary 30.10 2.00 1.67 
6 III serous primary 1.50 1.67 2.33 
7 III serous primary 20.70 1.00 2.00 
8 II serous primary 29.13 1.00 2.33 
9   serous primary 56.40 2.00 2.67 
12 III serous primary 23.00 1.00 2.00 
13   serous primary 34.43 2.00 2.67 
16 III serous primary 33.57 2.00 2.00 
17 III serous primary 6.60 1.00 3.00 
20 III serous primary 4.13 1.67 2.00 
21 III serous primary 37.90 1.00 2.67 
22 III serous primary 27.90 1.33 2.00 
23   serous primary 14.33 1.33 2.67 
24 III serous primary 54.35 1.00 3.00 
25 III serous primary 61.07 2.00 2.00 
26 III serous primary 4.50 0.33 2.00 
31 III serous primary 40.07 2.00 3.00 
38 III serous primary 2.73 1.67 2.00 
39 III serous primary 56.85 1.33 3.00 
40 III serous primary 0.73 0.00 2.00 
41 III serous primary 7.37 0.33 2.00 
42 III serous primary 1.53 1.67 2.00 
43 III serous primary 15.93 0.00 3.00 
45 III serous primary 15.97 0.33 3.00 
46 III serous primary 2.77 2.00 2.33 
47 III serous primary 6.07 0.00 2.00 
49 II serous primary 20.83 2.00 3.00 
1 III serous metastasis 24.73 2.67 2.67 
2 III serous metastasis 1.33 1.67 2.00 
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3 III serous metastasis 38.87 0.00 3.00 
4 III serous metastasis 8.53 1.33 2.00 
6 III serous metastasis 5.60 0.33 2.00 
7 III serous metastasis 15.70 1.00 2.33 
8 II serous metastasis 14.97 0.33 2.00 
9   serous metastasis 54.20 3.00 3.00 
12 III serous metastasis 21.80 1.00 2.00 
13   serous metastasis 24.67 1.33 3.00 
16 III serous metastasis 25.43 1.00 2.00 
17 III serous metastasis 28.20 1.00 2.00 
20 III serous metastasis 6.37 0.00 1.33 
21 III serous metastasis 18.70 1.00 NA 
22 III serous metastasis 39.13 2.67 2.00 
23   serous metastasis 16.30 1.00 2.00 
24 III serous metastasis 42.97 2.33 2.00 
25 III serous metastasis 19.87 2.00 2.00 
26 III serous metastasis 7.00 0.33 2.50 
38 III serous metastasis 10.97 1.00 2.00 
39 III serous metastasis 33.10 1.00 3.00 
40 III serous metastasis 14.83 0.00 2.00 
41 III serous metastasis 17.57 0.00 2.67 
42 III serous metastasis 0.00 2.00 NA 
43 III serous metastasis 0.87 0.00 2.33 
45 III serous metastasis 19.13 0.00 3.00 
46 III serous metastasis 3.10 2.33 2.00 
47 III serous metastasis 7.60 1.00 2.00 
49 II serous metastasis 28.30 NA 3.00 
31 III serous recurrence 11.20 2.00 3.00 
38 III serous recurrence 11.23 1.67 2.00 
39 III serous recurrence 60.17 1.00 3.00 
40 III serous recurrence 8.50 2.00 2.00 
41 III serous recurrence 12.13 0.67 2.00 
42 III serous recurrence 0.77 1.33 2.00 
43 III serous recurrence 0.20 0.67 3.00 
45 III serous recurrence 26.57 0.00 3.00 
46 III serous recurrence 1.93 2.33 2.33 
47 III serous recurrence 12.40 1.00 1.00 
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10 II mixed primary 1.20 0.67 1.33 
18 III mixed primary 42.20 1.67 2.00 
19 III mixed primary 15.43 1.00 2.33 
27 III mixed primary 44.50 0.67 2.00 
28 III mixed primary 24.53 0.33 2.00 
29 III mixed primary 7.97 0.00 3.00 
30 III mixed primary 13.33 1.33 2.67 
32 II mixed primary 43.10 2.00 2.00 
33 III mixed primary 11.60 0.00 2.00 
34 III mixed primary 1.23 0.33 2.00 
35 III mixed primary 1.23 1.00 1.00 
36 III mixed primary 0.47 0.00 2.00 
44 III mixed primary 21.43 0.67 2.00 
48 III mixed primary 16.10 1.00 1.00 
10 II mixed metastasis 30.23 0.33 2.00 
18 III mixed metastasis 4.50 1.00 2.00 
19 III mixed metastasis 24.17 1.00 3.00 
34 III mixed metastasis 4.13 0.33 2.00 
35 III mixed metastasis 1.30 1.67 1.00 
36 III mixed metastasis 2.13 0.00 2.00 
44 III mixed metastasis 11.23 1.00 2.00 
48 III mixed metastasis 5.70 1.00 2.00 
27 III mixed recurrence 12.67 0.67 2.00 
28 III mixed recurrence 12.37 1.00 1.33 
29 III mixed recurrence 11.10 0.00 3.00 
30 III mixed recurrence 14.00 1.00 2.67 
32 II mixed recurrence 3.27 1.33 3.00 
33 III mixed recurrence 38.47 1.33 3.00 
34 III mixed recurrence 1.30 0.00 2.00 
35 III mixed recurrence 3.73 1.00 1.00 
36 III mixed recurrence 0.30 1.00 2.00 
44 III mixed recurrence 10.83 0.67 2.00 
48 III mixed recurrence 4.90 1.00 1.00 
5 III other primary 27.13 0.00 3.00 
11 III other primary 19.27 1.33 2.67 
14 III other primary 10.37 0.00 2.00 
15 III other primary 17.70 0.67 2.00 
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5 III other metastasis 31.83 1.00 3.00 
11 III other metastasis 1.83 1.33 2.33 
14 III other metastasis 5.23 0.00 1.67 
15 III other metastasis 40.73 1.67 2.33 
37 III not EOC primary 10.57 0.33 3.00 
37 III not EOC metastasis 4.53 1.00 2.00 
37 III not EOC recurrence 30.87 1.00 2.00 
 Tumors are listed by de-identified patient sample # with corresponding tumor grade (most are FIGO 
grade III), pathology histological subtype (histosubtype; serous, mixed, other, and not EOC), tumor type 
(primary, metastasis, recurrence), and average scores for KDM4B nuclear staining (% nuclear staining), 
PDGFB intensity scores (0-3, in increments of 0.3), and CA9 intensity scores (0-3, in increments of 0.3). 
Scoring was applied as described in Supplemental Methods, using triplicate spots. Data are ranked by 
histosubtype, then tumor type, then patient sample #. Sections with damaged spots during IHC are 
labeled “NA” 
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small size of the sample set, and the overall heterogeneity of ovarian cancer (Cancer 
Genome Atlas Research 2011; Tan et al. 2013), these findings provide robust support 
for our hypothesis that KDM4B expression in hypoxic tumor tissue leads to the 
expression of genes that facilitate peritoneal dissemination (Apte et al. 2004). 
 
DISCUSSION 
Emerging evidence has indicated that dysregulation of histone demethylases 
play important roles in tumorigenesis (Berry and Janknecht 2013; Hojfeldt et al. 2013). 
The JmjC domain containing histone demethylase KDM4B is overexpressed in many 
cancers and plays important roles in cancer proliferation, DNA repair and metastasis 
(Young et al. 2013; Zhao et al. 2013f; Berry et al. 2014). A few studies have reported 
KDM4B function in cancer metastasis. In gastric cancer and colon cancer, KDM4B has 
been shown to interact with β-catenin in regulating gene expression (Zhao et al. 2013f; 
Berry et al. 2014). In the last chapter, we have demonstrated that KDM4B directly 
regulated the expression of metastatic genes, such as PDGFB, LCN2, LOX and LOXL2, 
in ovarian cancer cells (Figure 2.9, 2.13 and 2.14). However, whether KDM4B 
functionally contributed to ovarian cancer metastasis was unknown.  
In this chapter, we have determined that KDM4B expression level was elevated 
in 2/3 of the primary, metastatic, or recurrent ovarian serous adenocarcinoma biopsies 
tested compared to normal ovarian tissue (Figure 3.1). KDM4B protein expression was 
induced by hypoxia in a penal of ovarian cancer cell lines (Figure 3.2). Loss of KDM4B 
by shRNA knockdown severely impaired in vitro EOC cell migration, invasion, and 
attachment-free growth, which are important aspects of the peritoneal dissemination 
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(Figure 3.4-3.6). When KDM4B was knocked down, in vivo EOC tumor growth and 
peritoneal dissemination in nude mice also decreased significantly (Figure 3.7-3.11).  
There has been little improvement in EOC patient mortality over the past 30 
years (Lengyel 2010). One main reason for the poor prognosis of EOC patients is that 
most of the patients are diagnosed at late-stage, where tumors have already spread 
throughout the peritoneal cavity (Lengyel 2010). The formation of malignant ascites 
filled with free-floating clusters of cancer cells adds more difficulty for effective removal 
of residual cancer cells. After the initial surgery and first-line treatment, EOC usually 
recurs within 2 to 5 years with chemo-resistant tumors. Therefore, it is important to 
study the underlying mechanism of EOC metastasis. 
In contrast to other tumor types, EOC metastasizes in a unique manner. The 
most common theory is that EOC cells detach from the primary ovarian tumor, grow as 
single cells or spheroids in peritoneal ascites fluid, and distribute throughout the 
peritoneum and omentum (Lengyel 2010). Multiple factors may facilitate spheroid 
formation, maintenance and ultimate establishment to secondary sites, including the 
epithelial-mesenchymal transition (EMT), binding of the integrins to the extracellular 
matrix, and activities of the MMPs (Lengyel 2010).  
Pradeep et al have recently shown that EOC cells may also use the traditional 
hematogeneous mechanism to migrate, with a strong predilection to seed on the 
omentum (Pradeep et al. 2014). They discovered that this tropism relied on the 
ErbB3/NRG1 signaling axis, whose ligand and target were overexpressed by the 
omental vascular microenvironment. Nieman et al showed that adipokines such as 
interleukin-8 (IL-8) can mediate homing, migration and invasion of ovarian cancer cells 
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to omental adipocytes (Nieman et al. 2011). They also detected fatty acid-binding 
protein 4 (FABP4) in ovarian cancer cells at the adipocyte-tumor cell interface, 
suggesting FABP4 may also play an important role in ovarian cancer metastasis to the 
omentum (Nieman et al. 2011). Hypoxia has been shown to induce the expression of 
fatty acid binding proteins, including FABP1, FABP3 and FABP4 in placental 
trophoblasts (Biron-Shental et al. 2007). Since trophoblasts invade stromal tissues in a 
manner very consistent with cancer cells, there is a clear parallel to ovarian cancer 
metastasis. Studying the intersection between hypoxia and fat metabolism in ovarian 
cancer may improve our understanding of the adipose-specific targeting of peritoneal 
metastases. 
The importance of hypoxic signaling as a potential therapeutic target in EOC was 
highlighted by the relative success of bevacizumab (Avastin) in the treatment of HGSA 
(Bast 2011), which targets the classical hypoxia-inducible vascular endothelial growth 
factor receptor (VEGFR). The ability to successfully target a hypoxia-inducible gene 
indicates that KDM4B and its downstream target genes may be useful for improving the 
effectiveness of cancer therapies.  
Another major challenge to effectively treat advanced stage ovarian cancer is 
that it is characterized by global genomic instability, suggesting that targeting a single 
pathway is not sufficient for complete removal of the cancer (Cancer Genome Atlas 
Research 2011). Therefore, it is important to study alternative mechanisms contributing 
to attachment-free growth of cancer cells in malignant ascites and invasion of cancer 
cells into the mesothelium in order to develop more effective methods to attenuate 
peritoneal dissemination. As a hypoxia-regulated gene that facilitates expression of 
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multiple tumorigenic pathways in normoxia and hypoxia, KDM4B or its regulated target 
genes may provide unique opportunities to tailor a combinatorial approach for those 
patients with elevated KDM4B or hypoxic tumor signatures.  
Our results implied that disrupting KDM4B function with an inhibitor of its 
demethylase activity could serve as a novel chemotherapeutic approach. Recent 
studies have devoted much effort to designing specific inhibitors of histone 
demethylases, with the greatest success restricted to inhibition of classes of jumonji 
domain histone demethylases, as in the case of the KDM6 family (Kruidenier et al. 
2012). While these studies show promise for the eventual development of inhibitors 
specific to families of JMJ-C domain histone demethylases, specificity to each of the 
more than 20 individual histone demethylases remain a major challenge. Given the 
important role of KDM4 family members in regulating various aspects of DNA repair, 
proliferation and embryonic development (Mallette et al. 2012; Young et al. 2013; Das et 
al. 2014), the inappropriate targeting of these enzymes may lead to severe side effects. 
Therefore, our ability to design inhibitors that specifically target KDM4B will be crucial in 
order to use KDM4B for therapeutic improvement. Moreover, the myriad genes 
regulated by KDM4B in SKOV3ip.1 cells indicate that multiple pathways are involved in 
supporting EOC metastasis. In order to improve therapy against metastatic EOC cells, 
our study provides multiple targeting opportunities, such as PDGFB, LCN2, LOX and 
LOXL2, to suppress the establishment of peritoneal tumors from malignant ascites. 
Blocking PDGFB signaling in SKOV3ip.1 cells with RNA aptamers suppresses growth of 
peritoneal tumor xenografts (Lu et al. 2010). Combinatorial targeting of other genes 
regulated by KDM4B in SKOV3ip.1 cells may lead to improved methods to suppress 
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peritoneal engraftment of EOC tumor cells, ultimately improving the prognosis of 
patients.  
Taken together, our study shows that KDM4B plays an important role in the 
peritoneal dissemination of EOC cells and may be used as a therapeutic target.  
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I. The Overall Importance of Our Study 
In this study, we have demonstrated that the hypoxia-inducible histone 
demethylase KDM4B regulates 16 common target genes in SKOV3ip.1 ovarian cancer, 
HCT116 colon cancer and RCC4 renal cell carcinoma cells. In SKOV3ip.1 cells, KDM4B 
regulates distinct pathways in different oxygen conditions, proliferative pathways in 
normoxia and metastatic pathways in hypoxia. KDM4B is a potent regulator of cellular 
processes that contribute to epithelial ovarian cancer (EOC) peritoneal dissemination. 
KDM4B is overexpressed in the majority of high-grade serous adenocarcinomas and 
ovarian cancer cell lines tested. Knockdown of KDM4B in two EOC cell lines results in a 
significant reduction in the peritoneal tumor load in vivo, consistent with the observed 
disruption of key phenotypes associated with peritoneal seeding (attachment-free 
growth, invasive behavior, and trans-well migration). By demonstrating KDM4B 
contribution to the metastatic phenotypes of EOC, our study suggests KDM4B or the 
genes that it specifically regulates in EOC cells may be useful targets to improve the 
prognosis of EOC patients. 
II. Regulation of Cancer Progression by KDM4B is Dependent on Cancer Type and 
Oxygen Tension 
KDM4B overexpression has been shown in multiple cancer types. It may be 
regulated by HIF, ER, AR and p53 in different tumor microenvironments to promote 
tumor survival (Beyer et al. 2008; Palomera-Sanchez et al. 2010; Coffey et al. 2013; 
Gaughan et al. 2013) (Figure 4.1). KDM4B regulates cancer cell proliferation (Kawazu 
et al. 2011; Kim et al. 2012a), anti-apoptosis (Sun et al. 2014), DNA damage repair 
(Mallette et al. 2012; Zheng et al. 2013; Chen et al. 2014), migration (Zhao et al. 2013f), 
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and embryonic development (Yoshioka et al. 2009; Ye et al. 2012; Das et al. 2014). 
Most of these functions are dependent on its histone demethylase activity regulating 
downstream pathways, including cell-cycle related genes (Yang et al. 2010; Kawazu et 
al. 2011; Kim et al. 2012a), anti-apoptotic genes like Bcl-2 (Sun et al. 2014), and other 
transcription factors (Zhao et al. 2013f; Berry et al. 2014; Das et al. 2014). KDM4B has 
been shown to interact with MLL2, an H3K4 demethylase, to activate gene expression 
(Figure 4.1). H3K4 methylation is usually found in the promoter region in active 
transcripts, indicating its role in gene activation (Ruthenburg et al. 2007). However, 
demethylase-independent function has also been reported of KDM4B, such as 
recruiting 53BP1 to DNA damage sites through its C-terminal interaction with di-
methylated H4K20 (Figure 4.1) (Mallette et al. 2012). In our study, KDM4B appeared to 
contribute to cancer progression by regulating both general and tissue-specific target 
genes. 
Common Regulation by KDM4B in Three Cancer Cell Lines 
In this study, we have used microarray analyses to identify potential targets of 
KDM4B in cancer cell lines derived from three different cancer types, including 
SKOV3ip.1 ovarian cancer, HCT116 colon cancer, and RCC4 renal cell carcinoma cells. 
These three cancer cell lines were chosen because they had shown dependence on 
hypoxic signaling during their development (Birner et al. 2001; Krishnamachary et al. 
2003; Gudas et al. 2014). There is also a lack of understanding in how KDM4B function 
in these cancers. Only four studies have been reported regarding KDM4B function and 
its target genes in colorectal cancer (CRC), with a few downstream pathways leading to  
 153 
Figure 4.1. Mechanisms used by KDM4B to promote cancer progression. KDM4B 
may be regulated by HIF, ER, AR and p53 in different tumor microenvironments to 
promote tumor survival. KDM4B has been shown to interact with MLL2, an H3K4 
demethylase, forming a complex to activate gene expression. KDM4A/B has been 
shown to inhibit 53BP1 recruitment to DNA damage sites by competitively binding to 
dimethylated H4K20. During DNA repair response, RNF8 ubiquitylates KDM4A/B, 
relieving H4K2me2 for 53BP1 recruitment. KDM4D is also recruited to DNA damage 
sites through a PARP1-dependent manner to promote double-strand break repair. As a 
closely related subfamily member, KDM4B may also be involved in DNA repair through 
similar mechanisms.   
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CRC proliferation and progression (Fu et al. 2012; Berry et al. 2014; Chen et al. 2014; 
Sun et al. 2014). Two studies showed elevated KDM4B expression level in renal cell 
carecinoma (RCC), yet no group has reported its molecular mechanism in RCC (Beyer 
et al. 2008; Krieg et al. 2010). To date, no study has been reported regarding KDM4B 
expression level or its function in epithelial ovarian cancer (EOC).  
By comparing KDM4B target genes in these three cell lines, we identified 16 
common targets that were regulated by KDM4B in all three cell lines. These genes 
display a variety of cellular functions, but are mostly related to cancer progression 
(Table 2.5 and Figures 2.3-2.6). Figure 4.2 illustrates this general regulation by KDM4B 
as a histone demethylase on target gene expression in hypoxic cancer cells. This 
finding indicates cancer cells, as heterogeneous as they are, may still share common 
mechanisms that can be targeted with general cancer therapies.  
Transcription factors and epigenetic regulators are known to play important roles 
in stem-cell differentiation and tumorigenesis through their ability to reprogram gene 
expression to establish certain cellular functions (Spivakov and Fisher 2007; Black et al. 
2012; Yang et al. 2013). Another commonly shared mechanism cancer cells use to 
promote their own survival and progression is the β-catenin transcription factor (Paul 
and Dey 2008). KDM4B has been reported to either induce or partner with β-catenin 
and its co-factor TCF-4 to regulate gene expression. One of the 16 commonly shared 
KDM4B targets in the three cell lines, DAZAP1, also has been shown to interact with 
TCF-4 and facilitate its binding to DNA. These findings indicate that multiple layers of 
regulation are involved in programing cancer cells for their progression to malignancy 
(Lukas et al. 2009). Understanding the regulation of such transcription factor complexes  
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Figure 4.2 General model of KDM4B function in cancer cell progression. Hypoxic 
microenvironment activates the HIF-1 transcription factor, which cooperates with ARNT 
activating the transcription of the KDM4B gene. KDM4B histone demethylase then 
catalyzes histone H3K9me3/me2 demethylation and activates transcription of target 
genes. These target genes may contribute to cancer cell migration, tumor metastasis, 
angiogenesis and inflammation.   
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by KDM4B will help us determine the advantages and disadvantages of using KDM4B 
as a therapeutic target.   
Regulation by KDM4B is Dependent on Cancer Type and Oxygen Level 
Cancer is a highly heterogeneous disease. Each cancer has its specific genetic 
mutations and pathological behaviors. Our current knowledge of KDM4B function in 
cancer points to mechanisms that are specific to each cancer type. For example, in 
breast cancer, KDM4B is regulated by the estrogen receptor and induces expression of 
pro-proliferative genes like Cyclin D1 (Yang et al. 2010). Androgens regulate KDM4B in 
prostate cancer, which in turn promotes PSA expression (Coffey et al. 2013). In colon 
and gastric cancers, KDM4B regulates β-catenin dependent gene expression and WNT 
signaling to promote attachment-free growth and metastatic behavior (Berry and 
Janknecht 2013; Zhao et al. 2013a). 
In our study, the three cancer cell lines shared only 16 common KDM4B targets, 
less than 6% of the total number of genes regulated by KDM4B in each cell line (Figure 
2.1). Ingenuity pathway analysis (IPA) also mapped out distinct pathways and disease 
states influenced by KDM4B in each cell type (Table 2.6-2.7). These pathway analyses 
showed that although RCC4 had a “pseudo-hypoxic” phenotype due to its lack of 
functional VHL, regulation by KDM4B in this cell line favored proliferative pathways, 
similar to its normoxic cohort of downstream pathways in HCT116 and SKOV3ip.1 
(Table 2.6), indicating KDM4B sensitivity to oxygen may play a critical role in its activity 
at target genes.  
KDM4B belongs to a family of JmjC-domain demethylases that removes methyl 
groups from histone lysine residues through hydroxylation, which requires oxygen 
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(Fodor et al. 2006; Tsukada et al. 2006). Therefore, it is reasonable that KDM4B 
function may be influenced by oxygen level.  
Indeed, we observed that KDM4B regulated distinct pathways in different oxygen 
conditions, which was most evident in SKOV3ip.1 cells. In normoxic condition, KDM4B 
regulated pathways more closely related to proliferation (cell cycle, cellular assembly, 
DNA replication/recombination/repair, and cell death), whereas pathways related to 
metastasis (cellular movement, cellular development, and cell-to-cell signaling) were 
preferentially regulated by KDM4B in hypoxia. This finding is significant because of the 
important role hypoxia plays in angiogenesis and metastasis (Erler et al. 2006; Yang et 
al. 2013). Induction of KDM4B in hypoxia seemed to further assist HIF regulation while 
its normoxic function focused on promoting tumor formation and survival.  
These findings suggest that KDM4B may play crucial yet distinct roles in each 
cancer type, even in each tumor microenvironment. Therefore, even though 
mechanisms of KDM4B functions have been shown in other cancer types, it is still 
important to further investigate how KDM4B contributes to the progression of ovarian 
cancer.  
III. Mechanism of KDM4B Function in Epithelial Ovarian Cancer 
Using microarray analysis, QPCR and ChIP, we have identified several target 
genes whose expression showed promising dependence on KDM4B expression, 
including LOX, LOXL2, PDGFB, and LCN2 (Chapter 2). LOX and LOXL2 are both 
members of the lysyl oxidase family, which comprises Cu2+- and lysine tyrosylquinone-
dependent amine oxidases (Decitre et al. 1998). LOX is involved in extracellular matrix 
(ECM) remodeling by crosslinking collagen for matrix metalloproteinase 2 (MMP2) 
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cleavage, thus promoting cell invasion and metastasis (Erler et al. 2006). LOXL2  
regulates extracellular and intracellular cell signaling pathways as well as function in 
ECM remodeling (Decitre et al. 1998). Studies have also shown that LOXL2 may play 
an important role in cell proliferation (Saad et al. 2010; Baker et al. 2011). These 
oxidases have been linked to poor prognosis in many cancer types (Erler et al. 2009; Le 
et al. 2009; Baker et al. 2011; Xiao and Ge 2012; Cox et al. 2013; Zaffryar-Eilot et al. 
2013).  
Our microarray analysis of three different cancer cell lines revealed LOXL2 as a 
common KDM4B target expressed in a hypoxia-inducible manner, indicating that it may 
play important roles in general cancer progression. We observed that transient 
knockdown of KDM4B robustly decreased the expression of LOXL2, however, the 
regulation was attenuated when KDM4B was stably knocked down with lentiviral 
shRNA. Our ChIP results confirmed direct interaction between KDM4B and LOXL2 
promoter, indicating KDM4B maybe one of several factors regulating the expression of 
LOXL2. As genes involved in a general cancer progression mechanism in multiple 
cancer types, having various pathways regulating the induction of these genes appear 
to give cancer cells a survival advantage. 
Among the list of KDM4B target genes, PDGFB and LCN2 expression most 
robustly followed the expression pattern of KDM4B. PDGFB is one of the secreted 
factors involved in promoting the recruitment of pericytes along the vascular endothelial 
cells, a process required in tumor angiogenesis (Chantrain et al. 2006). Pericytes 
function to stabilize the newly formed endothelial tubes, modulate blood flow and 
vascular permeability (Chantrain et al. 2006). They also regulate endothelial cell 
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proliferation, survival, migration, differentiation and branching (Chantrain et al. 2006). 
Growing evidence shows that pericytes are present along the microvasculature in 
human tumor tissues (Chantrain et al. 2006). Studies have also shown that anti-PDGF 
drugs significantly inhibited tumor growth and metastasis in tumors that express high 
levels of PDGFB (Hosaka et al. 2013). These findings suggest that KDM4B may 
contribute to EOC progression by promoting angiogenesis.  
LCN2 has multiple functions depending on its dimerization partner. It exists 
mainly as a monomer or a homodimer and is released by neutrophils and involved in 
innate immunity against bacterial infection (Goetz et al. 2002). LCN2 can also dimerize 
with matrix metalloproteinase 9 (MMP9) to protect it from degradation, thus promoting 
its gelatinolytic activity on ECM (Yan et al. 2001). LCN2 has been shown to have pro-
inflammatory functions and regulates cell growth and adhesion (Chakraborty et al. 
2012). Although LCN2 has also been shown to have anticancer activities by inhibiting 
angiogenesis and inducing apoptosis (Devireddy et al. 2005; Venkatesha et al. 2006; 
Tong et al. 2008), it serves as a potential oncogene in ovarian cancer (Cho and Kim 
2009). LCN2 expression level is significantly higher in multiple cancer types, including 
ovarian cancer, compared to their normal counter parts (Candido et al. 2014). 
Therefore, LCN2 demonstrates features of an interesting druggable target worth further 
investigation.  
Considering the large number of genes dependent on KDM4B in SKOV3ip.1 
cells, it is unclear at this time which specific genes or mechanistic pathways are 
primarily responsible for these broad phenotypic effects, although LCN2, LOX, LOXL2, 
and PDGFB make particularly compelling candidates with proven ability to influence 
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either ovarian cancer growth or general metastasis (Apte et al. 2004; Barker and Erler 
2011). Examining the individual contributions of the multiple genes regulated by KDM4B 
in SKOV3ip.1 and OVCAR8 cells should provide more insight into the specific 
mechanisms regulating peritoneal dissemination of EOC. 
IV. KDM4B Function in Ovarian Cancer 
In this study, we have also demonstrated the functional importance of KDM4B 
expression in EOC. Immunohistochemical (IHC) staining of tissue microarray (TMA) 
indicated that 2/3 of the primary, metastatic, or recurrent ovarian serous 
adenocarcinoma biopsies had increased KDM4B expression compared to normal 
ovarian epithelium (Chapter 3). Knocking down KDM4B significantly decreased the 
ability of cancer cells to migrate through the Boyden Chamber membrane, to invade 
through matrigel, and in attachment-free conditions. Our in vivo tumor xenograft study 
also showed that KDM4B knockdown significantly decreased peritoneal seeding and 
growth of OVCAR cells into tumors. The overall luciferase activity from the tumor cells 
and total tumor weight were both decreased by KDM4B knockdown.  
The metastatic behavior of ovarian cancer is unique in a sense that cells rarely 
travel through the blood vessels to secondary sites (Lengyel 2010). OVCAR cells 
detach from the primary ovarian tumor, grow as single cells or spheroids in peritoneal 
ascites fluid, and are carried by the physiological movement of the ascites to the 
peritoneum and omentum (Lengyel 2010). Multiple factors may facilitate spheroid 
formation, maintenance and ultimate establishment to secondary sites (Figure 4.3). 
Initial detachment of OVCAR cells from their primary tumor site involves the epithelial-
mesenchymal transition (EMT), which includes loss of E-cadherin expression and  
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Figure 4.3. Mechanism of the contribution of KDM4B signaling to ovarian cancer 
progression. Briefly, hypoxia induces the expression of KDM4B histone demethylase, 
which catalyzes histone H3K9me3/me2 demethylation at target promoters and 
enhances expression of genes involved in attachment-free growth in the peritoneal 
cavity, as well as enhancing invasion and migration of cancer cells to facilitate the 
formation of metastases in the viscera and peritoneal wall.  
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increased level of other cadherins (Veatch et al. 1994; Patel et al. 2003; Elloul et al. 
2005; Symowicz et al. 2007; Hudson et al. 2008). The E-cadherin ectodomain is 
cleaved by MMP9, which is induced by clustering of collagen binding integrins (α2β1- 
and α3β1-integrin) on the cancer cells, contributing to their shedding into ascites 
(Symowicz et al. 2007; Lengyel 2010). Active membrane type 1-MMP (MT1-
MMP/MMP14) on cancer cells cleaves α3-integrin, contributing to the detachment of the 
spheroid from the primary tumor (Moss et al. 2009). Once shed, OVCAR cells grow as 
spheroids suspended in ascites fluid accumulated in the peritoneal cavity. These 
spheroids express high levels of the α5β1-, α6β1- and α2β1-integrins, which bind to 
fibronectin, laminin and type IV collagen, respectively. These extracellular matrix 
proteins are abundantly present in ascites and in the mesothelium covering the 
peritoneum and the omentum (Casey et al. 2001; Lengyel 2010). Therefore, expression 
of these integrins by spheroids supports their growth in ascites and their eventual 
adhesion to secondary sites. MMP2 is also preferentially secreted by spheroids than by 
cells cultured in monolayer, possibly promoting disaggregation of the spheroids upon 
adhesion to mesothelial cell layers (Lengyel 2010). 
Our results indicate that KDM4B is involved in supporting spheroid formation and 
growth in ascites, as well as cell invasion through the mesothelium (Figure 4.3). These 
two features are the main factors causing poor prognosis in EOC. Therefore, KDM4B 
holds interesting therapeutic potential worth further investigation. 
V. Relevance of our study: KDM4B as a possible therapeutic target in ovarian 
cancer 
The treatment of EOC, particularly high grade serous adenocarcinoma (HGSA) is 
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a significant health problem. Because of the difficulty of detecting early stages of the 
disease, there has been little improvement in patient mortality over the past 30 years 
(Lengyel 2010). The primary factor in determining the prognosis of epithelial ovarian 
cancer patients is the degree of peritoneal metastasis at the time of diagnosis (Lengyel 
2010). The majority of ovarian serous adenocarcinoma patients are diagnosed with 
metastatic nodules distributed throughout the abdominal cavity, creating a baseline 
tumor load that hampers removal of residual microscopic tumors. Malignant ascites 
filled with free-floating clusters of cancer cells is another barrier to effective removal of 
residual cancer cell. After surgical debulking and treatment with carboplatin and 
paclitaxel, recurrent chemo-resistant tumors regain proliferative behavior and reseed 
the peritoneal cavity within 2 to 5 years, causing mortality through constriction of the 
visceral tissues and patient cachexia. Developing more effective methods to attenuate 
peritoneal dissemination and tumor recurrence depends on improved understanding of 
the underlying processes contributing to attachment-free growth of cancer cells in 
malignant ascites, invasion of cancer cells into the mesothelium, and establishment of 
new tumors. In this regard, hypoxia-inducible genes like KDM4B may represent an 
untapped resource for developing improved diagnostics or therapeutics for EOC 
patients. 
The importance of hypoxic signaling as a potential therapeutic target in EOC is 
highlighted by the relative success of bevacizumab (Avastin) in the treatment of HGSA 
(Bast 2011). Bevacizumab targets the receptor of vascular endothelial growth factor 
(VEGF), which is a classical hypoxia-induced pathway. The ability to successfully target 
a hypoxia-inducible gene indicate that KDM4B and its downstream target genes may be 
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useful for improving the effectiveness of cancer therapies. Although only 25% of HGSA 
patients responded to bevacizumab, with an average increase in disease-free survival 
of 4 months, this effect was more robust than all other alternate chemotherapies tested 
to date. Bevacizumab has documented limitations as a general therapeutic stemming 
from deleterious side effects (e.g. pleural effusions and intestinal perforations), or 
upregulation of compensatory hypoxic expression stemming from tumor starvation 
(Conley and Wicha 2012). As a hypoxia-regulated gene that facilitates expression of 
multiple tumorigenic pathways in normoxia and hypoxia, KDM4B or its regulated target 
genes may provide unique opportunities to tailor a combinatorial approach for those 
patients with elevated KDM4B or hypoxic tumor signatures.  
A key question rising from our study regards the utility of targeting KDM4B to 
improve EOC patient outcome. Although a systematic comparison has not been 
conducted, KDM4B appears to regulate pathways distinct to each cancer type (Yang et 
al. 2010; Coffey et al. 2013; Zhao et al. 2013f; Berry et al. 2014). In our experiments, 
although KDM4B regulates distinct pathways in different oxygen tensions, invasive and 
migratory behaviors appear to be the most robust phenotypes. In all cases, there is the 
implication that disrupting KDM4B function with an inhibitor of its demethylase activity 
could serve as a novel chemotherapeutic approach. More generally, there has been a 
great deal of effort devoted to designing specific inhibitors of histone demethylases, with 
the greatest success restricted to inhibition of classes of jumonji domain histone 
demethylases, as in the case of the KDM6 family (Kruidenier et al. 2012). While these 
studies show promise for the eventual development of inhibitors specific to families of 
JMJ-C domain histone demethylases, there remain significant barriers to creating a 
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specific inhibitor against each of the more than 20 individual histone demethylases. 
Particularly given the important role of KDM4A and KDM4B in regulating various 
aspects of DNA repair and proliferation (Mallette et al. 2012; Young et al. 2013), the 
inappropriate targeting of these enzymes using non-specific inhibitors would probably 
not represent a significant improvement over existing anti-proliferatives like carboplatin 
and paclitaxel. In contrast, the myriad genes regulated by KDM4B in SKOV3ip.1 cells 
provide multiple opportunities to suppress the establishment of peritoneal tumors from 
malignant ascites. Genes like PDGFB, LCN2, LOX and LOXL2 likely represent a small 
fraction of the types of secreted genes expressed in EOC that could eventually be 
targeted. As an independent proof of concept, blocking PDGFB signaling in SKOV3ip.1 
cells with RNA aptamers suppresses growth of peritoneal tumor xenografts (Lu et al. 
2010). Combinatorial targeting of other genes regulated by KDM4B in SKOV3ip.1 cells 
may lead to improved methods to suppress peritoneal engraftment of EOC tumor cells, 
ultimately improving the prognosis of patients. 
VI. Future directions 
Our findings in this study have raised several interesting questions. The first one 
regards how KDM4B function may differ in cycling versus prolonged hypoxia. In the 
actual hypoxic tumor microenvironment, tumor cells may experience both prolonged 
and fluctuating hypoxia caused by ischemia followed by reperfusion (Olbryt et al. 2014; 
Tellier et al. 2015). Cycling hypoxia has been shown to enhance tumor-promoting 
inflammation by inducing an amplified inflammatory phenotype in endothelial cells 
(Tellier et al. 2015). Some of the hypoxia-inducible genes that play important roles in 
leading to cancer malignancy require oxygen for their enzymatic functions. For example, 
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LOX protein expression is significantly increased by hypoxia, whereas its catalytic 
activity is reduced in low oxygen conditions (Postovit et al. 2008). The 
hypoxia/reoxygenation cycle plays a significant role in LOX function by up-regulating its 
expression in hypoxia and maximizing it catalytic activity with reoxygenation (Postovit et 
al. 2008). Normal KDM4B demethylase function also requires oxygen and hypoxia has 
been shown to reduce KDM4B activity (Beyer et al. 2008).  Therefore, it is important to 
study how KDM4B function may differ in cycling hypoxia compared to prolonged 
hypoxia. Given the pathways differentially regulated in normal or low oxygen conditions, 
we hypothesize that the hypoxia/reoxygenation cycling may be a preferred 
microenvironment for KDM4B to exert its full function in promoting cancer progression. 
Another question was raised regarding the potential functional compensation to 
the loss of KDM4B from the other KDM4 family members, which have shown synergistic 
functions with KDM4B in regulating embryonic development (Iwamori et al. 2011; 
Tsurumi et al. 2013; Das et al. 2014). Our results showed that KDM4D mRNA 
expression was increased when KDM4B was knocked down in OVCAR8 cells. KDM4D 
protein level increased with shK-1 knockdown in both SKOV3ip.1 and OVCAR8 cell 
lines. These results indicate that KDM4D may play a role in compensating to loss of 
KDM4B function. Although KDM4A and KDM4C expression did not change significantly 
upon loss of KDM4B, it is still possible that they may functionally compensate to 
regulate target gene expression. In order to test this hypothesis, Chromatin IP with 
KDM4D, KDM4A and KDM4C antibodies will be a useful method to confirm direct 
interaction between these histone demethylases and KDM4B target gene promoters. An 
inhibitor against the KDM4 family, ML324, is available and may be used to test the 
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potential effect of targeting all members of the KDM4 family. Knocking down KDM4D, 
KDM4A or KDM4C along with KDM4B knockdown will also determine the potential 
mechanism of compensation.  
Results from our expression and ChIP analyses indicated that KDM4B might not 
be the only factor influencing the expression of target genes like PDGFB, LCN2 and 
LOXL2 (Figure 3.13-14). Stable knockdown with shRNA showed modest decrease in 
LOXL2 mRNA expression compared to transient knockdown experiment with siRNA 
(Figure 2.13), even though KDM4B enrichment at the LOXL2 promoter still showed 
significant difference (Figure 2.14). There was also a general decrease of H3K9me3 
level on the PDGFB, LCN2 and LOXL2 promoters in hypoxia compared to normoxia, 
even though there was still a significant KDM4B-dependent change (Figure 2.14). 
Despite the potential compensatory mechanism from other KDM4 family members, 
KDM4B may also interact with other factors to co-activate gene expression. Studies 
have shown that KDM4B can interact with MLL2, ER, AR and β-catenin in regulating 
gene expression in breast cancer (Shi et al. 2011; Coffey et al. 2013; Gaughan et al. 
2013; Zhao et al. 2013f). To fully understand how KDM4B regulates the expression of 
these target genes, it would be important to identify KDM4B co-activators in each tumor 
microenvironment. Moreover, KDM4B demethylase-independent activity has also been 
demonstrated in the context of DNA repair (Mallette et al. 2012). In order to validate the 
demethylase-dependence of KDM4B activity, mutagenesis will be used for each domain 
of the KDM4B gene and cells expressing each construct will be tested for disruption in 
target gene expression and cellular functions.  
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VII. Significance 
Taken collectively, we have determined that the hypoxia-inducible histone 
demethylase KDM4B regulates general, tissue-specific, and oxygen dependent 
pathways in cancer progression. It is robustly expressed in the majority of EOC tumors 
assayed and regulates pathways to support cellular functions associated with peritoneal 
dissemination of cancer cells, the primary cause of EOC patient morbidity and mortality. 
KDM4B or the genes that it specifically regulates in EOC cells may be useful targets to 
improve the prognosis of EOC patients. 
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